NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)

Cancer- and Chemotherapy-Induced Anemia


NCCN.org
Cancer- and Chemotherapy-Induced Anemia

*George M. Rodgers, III, MD, PhD/Chair ‡
Huntsman Cancer Institute
at the University of Utah

*Jeffrey A. Gilreath, PharmD/Vice Chair ∑ ‡
Huntsman Cancer Institute
at the University of Utah

Maureen M. Achebe, MD, MPH ‡
Dana-Farber/Brigham and
Women's Cancer Center

Laura Alwan, PharmD ∑
Fred Hutchinson Cancer Research Center/
Seattle Cancer Care Alliance

Murat Arcasoy, MD ‡
Duke Cancer Institute

Seema Ali Bhat, MD † ‡
Roswell Park
Cancer Institute

Rondeep Brar, MD † ‡
Stanford Cancer Institute

David Cella, PhD θ
Robert H. Lurie Comprehensive Cancer
Center of Northwestern University

Peter F. Coccia, MD ≠ ‡ €
Fred & Pamela Buffett Cancer Center

Benjamin Djulbegovic, MD, PhD † ‡ ζ
Moffitt Cancer Center

Jennifer R. Green, MD ‡
Vanderbilt-Ingram Cancer Center

Stefanie L. Houseknecht, PharmD ∑
UC San Diego
Moore's Cancer Center

Eric H. Kraut, MD ‡
The Ohio State University Comprehensive
Cancer Center - James Cancer Hospital
and Solove Research Institute

Michael Kroll, MD ‡
The University of Texas
MD Anderson Cancer Center

Michael M. Millenson, MD † ‡
Fox Chase Cancer Center

Anne Neff, MD ‡
Case Comprehensive Cancer Center/
University Hospitals Seidman Cancer Center and
Cleveland Clinic Taussig Cancer Institute

Cindy L. O'Bryant, PharmD ∑ †
University of Colorado
Cancer Center

Rekha Parameswaran, MD ‡
Memorial Sloan Kettering Cancer Center

Rita Paschal, MD † ‡
University of Alabama at Birmingham
Comprehensive Cancer Center

Denise Reinke, MS, NP # †
University of Michigan
Comprehensive Cancer Center

Candido Rivera, MD ‡
Mayo Clinic Cancer Center

Joseph Rosenthal, MD ‡ €
City of Hope Comprehensive
Cancer Center

Satish Shanbhag, MBBS, MPH † ‡
The Sidney Kimmel Comprehensive
Cancer Center at Johns Hopkins

Ari VanderWalde, MD, MPH † ‡
St. Jude Children’s
Research Hospital/
The University of Tennessee
Health Science Center

Jennifer Burns
Courtney Smith, PhD

NCCN Guidelines Panel Disclosures
NCCN Guidelines Version 2.2017 Table of Contents

Cancer- and Chemotherapy-Induced Anemia

NCCN Cancer- and Chemotherapy-Induced Anemia Panel Members

Summary of the Guidelines Updates

Evaluation of Anemia (ANEM-1)

Risk Assessment and Indications for Initial Transfusion in Acute Setting (ANEM-2)

Risks and Goals of ESA Use Versus Red Blood Cell Transfusion (ANEM-3)

Special Categories in Considering ESA Use (ANEM-4)

Evaluation of Iron Deficiency (ANEM-5)

Indications for Red Blood Cell Transfusion in Patients (ANEM-A)

Erythropoietic Therapy - Dosing, Titration, and Adverse Effects (ANEM-B)

REMS: Risk Evaluation and Mitigation Strategy for Erythropoiesis-Stimulating Agents (ESAs) (ANEM-C)

Parenteral Iron Preparations (ANEM-D)

Management of Cancer- and Chemotherapy-Induced Anemia For Patients Who Refuse Blood Transfusions (ANEM-E)

Clinical Trials: NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

To find clinical trials online at NCCN Member Institutions, click here: nccn.org/clinical_trials/physician.html.

NCCN Categories of Evidence and Consensus: All recommendations are category 2A unless otherwise specified.

See NCCN Categories of Evidence and Consensus.
ANEM-1
- Evaluate anemia for possible cause
  - Third sub-bullet: After hemolysis, "Coombs test" has been changed to "direct antiglobulin test [DAT]."
  - "Low Epo" has been removed from the criteria for renal dysfunction.
  - If no cause of anemia identified, the following has been removed: "Consider anemia of chronic inflammation or anemia due to myelosuppressive chemotherapy."
- Footnotes:
  - Footnote "c" has been added: "Correct reticulocyte count for degree of anemia. See Discussion."
  - Footnote "d" has been revised: "Additionally, if serum iron studies are not performed while the patient is fasting or if the patient has taken an oral iron tablet, serum iron levels may be falsely elevated, and thus also falsely elevate the percent transferrin saturation. Fasting is preferred when testing for serum iron, total iron-binding capacity, and serum ferritin."

ANEM-2
- "Anemia of chronic inflammation or anemia due to myelosuppressive chemotherapy for lymphoid malignancies and solid tumors" has been changed to "Anemia in patients with cancer."
- High risk or Asymptomatic with comorbidities, first comorbidity revised: "Cardiac disease including transfusion-associated circulatory overload (TACO) and coronary heart disease"

ANEM-3
- The introductory statement has been revised for clarification: "If anemia is not due to absolute or functional iron deficiency, there are currently only two proven methods of improving Hb: ESAs and red blood cell transfusion. Listed below are risks and goals of each method anemia treatment."
- The following potential risks have been added under red blood cell transfusion:
  - Alloimmunization
  - Increased risk of poor response to future platelet transfusions due to HLA immunization

ANEM-4
- "For select patients who refuse blood transfusions" has been added as a special category with a recommendation for consideration of ESA use by FDA indications/dosing/dosing adjustments, under REMS guidelines, with informed consent of the patient.
- The recommendation for patients with cancer not receiving therapy, or patients not receiving myelosuppressive chemotherapy, or patients receiving myelosuppressive chemotherapy with curative intent, has been clarified: "There is not enough evidence to support ESA use in these patient populations, therefore ESAs are not recommended at this time."

ANEM-5
- Definition of functional iron deficiency has been revised: "ferritin 30–800 AND TSAT 20–<50%.
- The following options have been added for patients with possible functional iron deficiency (ferritin >500–800 ng/mL AND TSAT <50%):
  - No iron supplementation needed, or
  - Consider IV iron supplementation for select patients.
- Footnote "r" has been added: "Although patients with ferritin levels of >500–800 ng/mL may have functional iron deficiency, as evidenced by clinical trials in patients with cancer, there are insufficient data to support the routine use of IV iron in this setting. Administration of IV iron to such patients should be individualized with the goal of avoiding allogeneic transfusion."

Continued on next page
Updates in Version 1.2017 of the NCCN Guidelines for Cancer- and Chemotherapy-Induced Anemia from Version 2.2016 include:

**ANEM-A**
- The page heading has been revised: "Indications for Red Blood Cell Transfusions in Patients"
- Asymptomatic, hemodynamically stable chronic anemia, first sub-bullet revised: "Transfusion goal to maintain Hb >7–9 g/dL."
- For symptomatic anemia, hemoglobin (Hb) values have been removed.

**ANEM-B (3 of 5)**
- Bullet has been added: "Recent studies suggest that use of ESAs may be deleterious when used in patients with metastatic breast cancer. See Discussion."

**ANEM-B (4 of 5)**
- The following line in the last bullet has been revised: "ESAs should be permanently discontinued in patients with antibody-mediated anemia."

**ANEM-D (1 of 3)**
- Addition to footnote "b": "Ferumoxytol may cause interference with MRI scans causing potential false interpretation of organ iron overload."

**ANEM-D (2 of 3)**
- Test doses have been revised as follows:
  - Low-molecular-weight iron dextran: "Test dose required: 25 mg slow IV push and wait 1 h before giving remainder of dose"
  - Ferric Gluconate and Iron Sucrose: Test doses were replaced with the following: "Test dose at MD discretion based on risk factors for reaction."
  - 25 mg slow IV push or infusion

**ANEM-D (3 of 3)**
- The following references have been added:

**ANEM-E**
- A new page has been added, titled: "Management of Cancer- and Chemotherapy-Induced Anemia for Patients Who Refuse Blood Transfusions"
HEMOGLOBIN CONCENTRATION TO PROMPT AN EVALUATION OF ANEMIA

Hemoglobin (Hb) ≤11 g/dL or ≥2 g/dL below baseline

• CBC with indices
• Blood smear morphology

Evaluate anemia for possible cause as indicated\(^b\) (see Discussion):

- First check
  ‣ Reticulocyte count\(^c\) and mean corpuscular volume (MCV)
- Then consider
  ‣ Hemorrhage (stool guaiac, endoscopy)
  ‣ Hemolysis (direct antiglobulin test [DAT], disseminated intravascular coagulation [DIC] panel, haptoglobin, indirect bilirubin, lactate dehydrogenase)
  ‣ Nutritional (iron, total iron-binding capacity, ferritin, B\(_{12}\), folate)\(^d\)
  ‣ Inherited (prior history, family history)
  ‣ Renal dysfunction (Glomerular filtration rate [GFR] <60 mL/min/1.73 m\(^2\))
  ‣ Radiation-induced myelosuppression
  ‣ See Evaluation of Iron Deficiency (ANEM-5)

Treat as indicated

No cause identified → See Risk Assessment and Indications for Transfusion (ANEM-2)

Myelodysplastic syndromes

See NCCN Guidelines for Myelodysplastic Syndromes

Myeloid malignancies or Acute lymphoblastic leukemia

Treat underlying disease per NCCN Guideline

See NCCN Guidelines Table of Contents

\(^a\)The NCCN Guidelines for Cancer- and Chemotherapy-Induced Anemia were formulated in reference to adult patients.

\(^b\)This is a basic evaluation for possible causes of anemia.

\(^c\)Correct reticulocyte count for degree of anemia. See Discussion.

\(^d\)The ferritin value indicating iron deficiency is laboratory-specific. In general, the lower the level of ferritin, the higher the probability that the patient has true iron deficiency anemia. However, in the cancer setting, be aware of a chronic inflammatory state, which may falsely elevate the serum ferritin. Additionally, if serum iron studies are not performed while the patient is fasting or if the patient has taken a recent oral iron tablet, serum iron levels may be falsely elevated, and thus also falsely elevate the percent transferrin saturation. Fasting is preferred when testing for serum iron, total iron-binding capacity, and serum ferritin.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
RISK ASSESSMENT AND INDICATIONS FOR INITIAL TRANSFUSION IN ACUTE SETTING

Asymptomatic without significant comorbidities:
- Observe
- Periodic re-evaluation

High risk (ie, progressive decline in Hb with recent intensive chemotherapy or radiation) or
Asymptomatic with comorbidities:
- Cardiac disease
- Chronic pulmonary disease
- Cerebral vascular disease

Consider red blood cell transfusion per guidelines
See Indications for Red Blood Cell Transfusion in Patients (ANEM-A)

Symptomatic (physiologic):
- Sustained tachycardia
- Tachypnea
- Chest pain
- Dyspnea on exertion
- Lightheadedness
- Syncope
- Severe fatigue preventing work and usual activity

Red blood cell transfusion per guidelines
See Indications for Red Blood Cell Transfusion in Patients (ANEM-A)

See Comparison of Risks and Goals of ESA Use Versus Red Blood Cell Transfusion (ANEM-3)
See Special Categories in Considering ESA Use (ANEM-4)

Degree of severity of comorbidities in combination with the degree of severity of anemia should be taken into consideration when initiating red blood cell transfusion.

Fatigue (FACT-F) and Anemia (FACT-An) subscales of the Functional Assessment of Cancer Therapy (FACT) and Brief Fatigue Inventory (BFI) are examples of standardized measures for assessing patient-reported fatigue.

Note: All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
Listed below are risks and goals of each anemia treatment.

<table>
<thead>
<tr>
<th></th>
<th>ESA in the Cancer Setting</th>
<th>Red Blood Cell Transfusion</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Risks</strong></td>
<td>• Increased thrombotic events</td>
<td>• Transfusion reactions (e.g., hemolytic, febrile, non-hemolytic, lung injury)</td>
</tr>
<tr>
<td></td>
<td>• Possible decreased survival</td>
<td>• Transfusion-associated circulatory overload (TACO)</td>
</tr>
<tr>
<td></td>
<td>• Time to tumor progression shortened</td>
<td>• Virus transmission (e.g., hepatitis, HIV)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Bacterial contamination</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Iron overload</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Increased thrombotic events</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Possible decreased survival</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Alloimmunization</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Increased risk of poor response to future platelet transfusions due to HLA immunization</td>
</tr>
<tr>
<td><strong>Goals</strong></td>
<td>• Transfusion avoidance</td>
<td>• Rapid increase of Hb and hematocrit levels</td>
</tr>
<tr>
<td></td>
<td>• Gradual improvement in anemia-related symptoms</td>
<td>• Rapid improvement in anemia-related symptoms</td>
</tr>
</tbody>
</table>

See Erythropoietic Therapy - Dosing, Titration, and Adverse Effects (ANEM-B)

See REMS: Risk Evaluation and Mitigation Strategy for Erythropoiesis-Stimulating Agents (ESAs) (ANEM-C)

See Discussion for detailed information regarding the risks and benefits of ESA use and red blood cell transfusion.

Note: All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
### SPECIAL CATEGORIES IN CONSIDERING ESA USE

**Cancer and chronic kidney disease (moderate to severe)**
- Consider ESAs by FDA indications/dosing/dosing adjustments for chronic kidney disease, under REMS guidelines, with informed consent of patient j,k,l,m

**Patient undergoing palliative treatment**
- Consider based on patient preferences:
  - ESAs by FDA indications/dosing/dosing adjustments, under REMS guidelines, with informed consent of patient j,k,l
  - Red blood cell transfusion per guidelines (See ANEM-A)

**Remainder of patients with anemia on myelosuppressive chemotherapy without other identifiable cause of anemia**
- Consider based on patient preferences:
  - ESAs by FDA indications/dosing/dosing adjustments, under REMS guidelines, with informed consent of patient j,k,l
  - Red blood cell transfusion per guidelines (See ANEM-A)
  - Clinical trial

**Select patients who refuse blood transfusions**
- Consider ESAs by FDA indications/dosing/dosing adjustments, under REMS guidelines, with informed consent of patient j,k,l
- See Management of Patients Who Refuse Blood Transfusions (ANEM-E)

- There is not enough evidence to support ESA use in these patient populations, therefore ESAs are not recommended at this time

- **Patients with cancer not receiving therapy**
- **Patients receiving non-myelosuppressive therapy**
- **Patients receiving myelosuppressive chemotherapy with curative intent**

  (Examples of cancers for which there is therapy with curative intent: Early-stage breast cancer, Hodgkin lymphoma, non-Hodgkin lymphomas, testicular cancer, early-stage non-small cell lung cancer, small cell lung cancer, etc.)

  - See Comparison of Risks and Goals of ESA Use Versus Red Blood Cell Transfusion (ANEM-3).

  - A few studies suggest that patients with small cell lung cancer on myelosuppressive chemotherapy may not have an increase in mortality when receiving ESAs. Oncologic Drugs Advisory Committee March 2008; Pirker et al. J Clin Oncol 2008; 26:2342-3249; Grote et al. J Clin Oncol 2005;23:9377-9386. (See Erythropoietic Therapy - Dosing, Titration, and Adverse Effects (ANEM-B).

  - Health care providers prescribing ESAs need to enroll in the ESA APPRISE Oncology Program. See REMS: Risk Evaluation and Mitigation Strategy for Erythropoiesis-Stimulating Agents (ESAs) (ANEM-C).

  - Patients with previous risk factors for thrombosis are at higher risk for thrombosis with the use of ESAs. If considering use of ESAs, evaluate the risk factors for thrombosis: history of thromboembolism, known heritable mutation, hypercoagulability, elevated pre-chemotherapy platelet counts, hypertension, steroids, prolonged immobilization, recent surgery, certain therapies for multiple myeloma, hormonal agents, etc. (See NCCN Guidelines for Cancer-Associated Venous Thromboembolic Disease).

  - The hemoglobin threshold for treatment and dosing with ESAs is different for chemotherapy-induced anemia and chronic kidney disease. For more details on the use of ESAs in patients with cancer and chronic kidney disease, see Discussion.

---

**Note:** All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
EVALUATION OF IRON DEFICIENCY

<table>
<thead>
<tr>
<th>IRON STATUS</th>
<th>MANAGEMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Absolute iron deficiency&lt;sup&gt;n&lt;/sup&gt; (ferritin &lt;30 ng/mL AND TSAT &lt;20%)</td>
<td>Consider IV or oral iron supplementation</td>
</tr>
<tr>
<td></td>
<td>Hb increases after 4 wk</td>
</tr>
<tr>
<td></td>
<td>No Hb increase after 4 wk</td>
</tr>
<tr>
<td>Functional iron deficiency in patients receiving ESAs&lt;sup&gt;o,p&lt;/sup&gt;</td>
<td>Consider IV iron supplementation&lt;sup&gt;r,s,t&lt;/sup&gt; with erythropoietic therapy</td>
</tr>
<tr>
<td>(ferritin 30–500 ng/mL AND TSAT &lt;50%)</td>
<td>See Discussion for clinical examples of iron status</td>
</tr>
<tr>
<td>Possible functional iron deficiency&lt;sup&gt;o,p,q&lt;/sup&gt; (ferritin &gt;500–800 ng/mL AND TSAT &lt;50%)</td>
<td>No iron supplementation needed or Consider IV iron supplementation for select patients</td>
</tr>
<tr>
<td>No iron deficiency (ferritin &gt;800 ng/mL OR TSAT ≥50%)</td>
<td>IV or oral iron supplementation is not needed</td>
</tr>
</tbody>
</table>

<sup>d</sup>The ferritin value indicating iron deficiency is laboratory-specific. In general, the lower the level of ferritin, the higher the probability that the patient has true iron deficiency anemia. However, in the cancer setting, be aware of a chronic inflammatory state, which may falsely elevate the serum ferritin. Additionally, if serum iron studies are not performed while the patient is fasting or if the patient has taken a recent oral iron tablet, serum iron levels may be falsely elevated, and thus also falsely elevate the percent transferrin saturation. Fasting is preferred when testing for serum iron, total iron-binding capacity, and serum ferritin.

<sup>n</sup>If the ferritin and TSAT are discordant, the low ferritin value should take precedence in determining whether IV iron will be of benefit.

<sup>o</sup>In clinical trials using IV iron plus an ESA, a higher response rate is seen when iron is used for patients with a TSAT <20%. For patients who received IV iron that had baseline TSATs >20%, the response rate to IV iron is both diminished and prolonged as the TSAT increased from 20% to 50%. Therefore, the decision to offer IV iron to this subset of patients should be reserved for those in whom benefits are likely to outweigh risks.

<sup>p</sup>Only 1 of 6 studies (Henry DH, et al. Oncologist 2007;12:231-242) of IV iron therapy in patients with cancer provided a TSAT guideline for monitoring.

<sup>q</sup>Although patients with ferritin levels of >500–800 ng/mL may have functional iron deficiency, as evidenced by clinical trials in patients with cancer, there are insufficient data to support the routine use of IV iron in this setting. Administration of IV iron to such patients should be individualized with the goal of avoiding allogeneic transfusion.

<sup>r</sup>IV iron has superior efficacy and should be considered for supplementation. Oral iron has been more commonly used but is less effective.

<sup>s</sup>Although all combinations of serum ferritin and TSAT could be found in at least one of six randomized controlled trials evaluating the use of IV iron with an ESA, eligibility criteria testing for serum ferritin and TSAT generally ranged from >10 to <900 ng/mL and >15% to <60%, respectively.

<sup>t</sup>There are insufficient data to routinely recommend IV iron as monotherapy without an ESA for the treatment of functional iron deficiency anemia.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
INDICATIONS FOR RED BLOOD CELL TRANSFUSION IN PATIENTS\textsuperscript{a,b,c}

Goal: Prevent or treat deficit of oxygen-carrying capacity in blood

\textbf{Asymptomatic Anemia}
- Hemodynamically stable chronic anemia:
  - Transfusion goal to achieve Hb >7 g/dL.

\textbf{Symptomatic Anemia}
- Acute hemorrhage with evidence of hemodynamic instability or inadequate oxygen delivery:
  - Transfuse to correct hemodynamic instability and maintain adequate oxygen delivery.
- Symptomatic (including tachycardia, tachypnea, postural hypotension) anemia:
  - Transfusion goal to maintain Hb as needed for prevention of symptoms.
- Anemia in setting of acute coronary syndromes or acute myocardial infarction:
  - Transfusion goal is unclear and is being evaluated. Consider clinical context and published guidelines.


\textsuperscript{b}If there is a regimen (either research or standard protocol) for which a higher hemoglobin is required for full-dose treatment, it would be acceptable to be more aggressive with the hemoglobin target.

\textsuperscript{c}See Management of Patients Who Refuse Blood Transfusions (ANEM-E).
### Erythropoietic Therapy - Dosing and Titration (1 of 5)

#### Initial Dosing

<table>
<thead>
<tr>
<th>Package Insert Dosing Schedule</th>
<th>Titration for No Response</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Epoetin alfa</strong> 150 units/kg 3 times per wk by subcutaneous injection or Epoetin alfa 40,000 units every wk by subcutaneous injection or Darbepoetin alfa 2.25 mcg/kg every wk by subcutaneous injection or Darbepoetin alfa 500 mcg* every 3 wks by subcutaneous injection</td>
<td>Increase dose of epoetin alfa to 300 units/kg 3 times per wk by subcutaneous injection or Increase dose of epoetin alfa to 60,000 units every wk by subcutaneous injection or Increase darbepoetin alfa to up to 4.5 mcg/kg every wk by subcutaneous injection or Increase darbepoetin alfa to up to 500 mcg fixed dose every 3 wks by subcutaneous injection</td>
</tr>
</tbody>
</table>

#### Alternative Regimens

| Darbepoetin alfa 100 mcg fixed dose every wk by subcutaneous injection or Darbepoetin alfa 200 mcg fixed dose every 2 wks by subcutaneous injection or Darbepoetin alfa 300 mcg* fixed dose every 3 wks by subcutaneous injection or Epoetin alfa 80,000 units every 2 wks by subcutaneous injection or Epoetin alfa 120,000 units every 3 wks by subcutaneous injection | Increase darbepoetin alfa to up to 150–200 mcg fixed dose every wk by subcutaneous injection or Increase darbepoetin alfa to up to 300 mcg fixed dose every 2 wks by subcutaneous injection or Increase darbepoetin alfa to up to 500 mcg fixed dose every 3 wks by subcutaneous injection or Increase darbepoetin alfa to up to 500 mcg fixed dose every 3 wks by subcutaneous injection |

*Data indicate that darbepoetin alfa 300 mcg is equivalent in terms of efficacy to darbepoetin alfa 500 mcg for initial dosing.*

---

**Note:** All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

---

See Footnotes and References (ANEM-B 2 of 5)

See Erythropoietic Therapy-Adverse Effects (ANEM-B 3 of 5)

---

Version 2.2017, 11/16/16 © National Comprehensive Cancer Network, Inc. 2016. All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®.
Footnotes


2 Less-frequent dosing regimens could be considered as an alternative to dose reduction.

3 The dosages and regimens included in this table have been evaluated in patients with cancer receiving chemotherapy.

4 IV iron has superior efficacy and should be considered for supplementation. Oral iron has been more commonly used but is less effective. (See Discussion for details.) See Parenteral Iron Preparations (ANEM-D).

References


Survival of Patients with Cancer

- Studies have reported possible decreased survival in patients with cancer receiving erythropoietic drugs for correction of anemia. Analyses of eight studies in patients with cancer found decreased survival in patients receiving erythropoietic drugs for correction of anemia and target Hb levels of >12 g/dL.\(^1\)\(^-\)\(^8\) One analysis in patients with cancer not receiving active therapy found decreased survival in patients treated with ESAs.\(^6\) Please refer to the FDA website for additional information: [http://www.fda.gov/cder/drug/infopage/RHE/default.htm](http://www.fda.gov/cder/drug/infopage/RHE/default.htm). Unless new evidence demonstrates a change in benefit: risk estimates, physicians should be advised not to administer ESAs (darbepoetin alfa, epoetin alfa) to patients outside of the treatment period of cancer-related chemotherapy. A treatment period is defined as anemia following initiation of therapy and continuing approximately 6 weeks after the completion of treatment.
- While three meta-analysis updates on survival have indicated an increased mortality risk with the use of ESAs,\(^9\)\(^-\)\(^12\) two meta-analyses have indicated that ESA use did not significantly affect mortality or disease progression.\(^13\)\(^,\)\(^14\)
- Recent pharmacovigilance trials have reported no adverse effects on survival in patients with cancer with chemotherapy-induced anemia receiving ESAs.\(^15\)\(^-\)\(^17\)
- The risks of shortened survival and tumor progression have not been excluded when ESAs have been dosed to a target Hb of <12 g/dL.
- Additional prospective clinical trials designed and powered to measure survival of patients with cancer are ongoing to provide clinicians with data to guide optimal use of erythropoietic agents.
- Because of the above issues, providers should inform patients of risks and benefits of ESA therapy versus red blood cell transfusion. (See Comparison of Risks and Goals of ESA Use Versus Red Blood Cell Transfusion - ANEM-3).
- Recent studies suggest that use of ESAs may be deleterious when used in patients with metastatic breast cancer. See Discussion.

Thrombosis

- Early trials of recombinant human erythropoietin reported that a high-target hematocrit (42 ± 3%) was found to have an increased number of vascular events (arterial and venous).
- Erythropoietin has a thrombogenic potential independent of Hb levels.\(^18\) Patients with previous risk factors for thrombosis may be at higher risk for thrombosis with the use of ESAs. If considering use of ESAs, evaluate the risk factors for thrombosis: history of thromboembolism, heritable mutation, hypercoagulability, elevated pre-chemotherapy platelet counts, hypertension, steroids, prolonged immobilization, recent surgery, certain therapies for multiple myeloma, hormonal agents, etc. (See NCCN Guidelines for Cancer-Associated Venous Thromboembolic Disease)
- Five meta-analyses reported an increase in relative risk of thrombotic events ranging from 48% to 69% with ESA use.\(^9\)\(^,\)\(^12\)\(^-\)\(^14\),\(^19\) The absolute risk of venous thromboembolism was 7.5% in patients treated with ESAs compared to 4.9% in control patients.\(^9\)
- A clinical trial in chronic kidney disease demonstrated a 92% increase in the relative risk of stroke (absolute risk 5.0% vs. 2.6%) with darbepoetin alfa.\(^20\)
Hypertension/Seizures

• Blood pressure should be controlled in all patients prior to initiating therapy with erythropoietic drugs and must be monitored regularly in treated patients.
• Seizures have been reported in patients with chronic renal failure receiving erythropoietic drugs.
• Hb level should be monitored to decrease the risk of hypertension and seizures. (See Titration for Response ANEM-B 1 of 5)

ESA-Neutralizing Antibodies (Pure red cell aplasia, PRCA)

• Between 1998–2004, 197 cases of PRCA were reported in patients treated with erythropoietin. Over 90% of these cases occurred with Eprex, an epoetin alfa product used outside of the United States. Patients who develop a loss of response to erythropoietic drugs should be evaluated for possible PRCA, and if present, all erythropoietic drugs should be discontinued.
• In 2005, the FDA's interpretation of anemia associated with neutralizing antibodies evolved to include both PRCA and severe anemia. Since 2005, FDA safety databases have included information on 30 new cases of antibody-associated PRCA, primarily associated with subcutaneous administration of epoetin alfa and darbepoetin alfa. This interpretation resulted in a class label change for all ESAs. The toxicity has been reported predominantly in patients with chronic renal failure receiving ESAs by subcutaneous administration. Any patient who develops a sudden loss of response to an ESA, accompanied by a severe anemia and low reticulocyte count, should be evaluated for the etiology of loss of effect, including the presence of neutralizing antibodies to erythropoietin. If anti-erythropoietin antibody-associated anemia is suspected, ESAs should be withheld and plasma should be sent for evaluation of assays for binding and neutralizing antibodies. ESAs should be discontinued in patients with antibody-mediated anemia. Patients should not be switched to other ESA products as antibodies may cross-react.
ERYTHROPOIETIC THERAPY - ADVERSE EFFECTS (5 OF 5)

ADVERSE EFFECTS REFERENCES


REMS: RISK EVALUATION AND MITIGATION STRATEGY FOR ERYTHROPOIESIS-STIMULATING AGENTS (ESAs)

• The FDA requires that ESAs be prescribed and used under a risk management program, known as a risk evaluation and mitigation strategy (REMS), to ensure that patients have been counseled on the risks and benefits of therapy and that therapy is not initiated until the patient’s signature is recorded acknowledging acceptance of the known risks.

• As part of REMS for ESAs1:
  ‣ Health care providers who prescribe ESAs to patients with cancer are required to enroll in the ESA APPRISE (Assisting Providers and Cancer Patients with Risk Information for the Safe use of ESAs) Oncology Program.
  ‣ Health care providers who prescribe ESAs should counsel each patient on the risks and benefits of ESAs prior to each new course of ESA therapy.
  ‣ The patient or patient representative must sign an ESA APPRISE Oncology Program Patient and Healthcare Provider Acknowledgment Form (https://www.esa-apprise.com/ESAAppriseUI/public/ESA_APPRISE_Oncology_Program_Acknowledgment_Form_PATIENT.pdf) in the presence of the health care provider to document that a risk:benefit discussion related to ESAs has occurred.
    ◊ The form must be signed before the patient begins a course of treatment with an ESA.
    ◊ Each patient must be provided with a copy of the signed form.
    ◊ Completed forms should be retained by the health care provider or hospital and must be made available to the ESA APPRISE Oncology Program for auditing purposes.

• Patients with cancer using ESAs should2:
  ‣ Understand the following risks associated with use of ESAs:
    ◊ ESAs may cause tumors to grow faster.
    ◊ ESAs may cause some patients to die sooner.
    ◊ ESAs may cause some patients to develop blood clots and serious heart problems such as a heart attack, heart failure, or stroke.
  ‣ Be aware that their health care professional has received special training about the use of ESAs in patients with cancer.
  ‣ Read the Medication Guide (See Epoetin Alfa Medication Guide and See Darbepoetin Alfa Medication Guide) to understand the benefits and risks of using an ESA.
  ‣ Talk with their health care professional about any questions they may have about using ESAs.
  ‣ Be aware that they must sign the Acknowledgment Form that says he or she has talked with his or her health care professional about the risks of ESAs before the first dose of an ESA can be received.

• For selected safety information for health care providers, see https://www.esa-apprise.com.

1Adapted from: https://www.esa-apprise.com/ESAAppriseUI/ESAAppriseUI/default.jsp#isi.
Parentseral iron preparations studied in patients with cancer.\(^b\)

- Low-molecular-weight iron dextran
- Ferric gluconate
- Iron sucrose
- Ferric carboxymaltose\(^a\)

Five\(^2-6\) of six\(^8\) studies have shown that parenteral iron products show improved Hb response rates in treating absolute or functional iron deficiency in patients with cancer who are receiving ESAs.

- None of the six studies provided instruction on how or when to redose iron after the initial cumulative dose has been given.
  - Generally, repeat iron studies are not recommended within 3 to 4 weeks of administration. Clinicians may consider repeating iron studies if/when the MCV is <80 fL, or if/when evidence of hypochromic red blood cells is seen in the peripheral blood.
  - If treatment with iron fails after 4 to 6 weeks and after the total intended dose has been administered, repeat iron studies may be considered.\(^5,8\) Patients should be monitored for evidence of iron overload, including signs and symptoms of cardiomyopathy, endocrinopathy, and hepatotoxicity. If evidence exists of iron overload, do not administer IV iron. Subsequent doses of iron should be withheld if the serum ferritin exceeds 1000 ng/mL\(^5,6\) or TSAT exceeds 50%.\(^2\)

- Test doses are required for low-molecular-weight iron dextran, but not for ferric gluconate, iron sucrose, or ferric carboxymaltose.
  - Test doses are strongly recommended for ferric gluconate and iron sucrose if patients have exhibited sensitivities to low-molecular-weight iron dextran or other IV iron preparations, or if they have multiple drug allergies.

- High-molecular-weight iron dextran is not recommended.\(^9,10\)

- Patients with an active infection should not receive IV iron therapy.

\(^a\) Ferric carboxymaltose has not been prospectively evaluated and therefore should only be considered when other parenteral iron preparations fail.\(^7\) Ferric carboxymaltose is indicated for adult patients when oral iron is not tolerated or there is a limited response. It is also indicated for patients with non-dialysis–dependent chronic kidney disease.\(^11,12\)

\(^b\) Ferumoxytol is indicated for the treatment of iron deficiency in adult patients with chronic kidney disease. There are no data to show the efficacy of ferumoxytol in patients with cancer. Ferumoxytol may cause interference with MRI scans causing potential false interpretation of organ iron overload.\(^13\)

\(^1-7\) (1 of 3)
## PARENTERAL IRON PREPARATIONS 

### RECOMMENDATIONS FOR ADMINISTERING PARENTERAL IRON PRODUCTS

<table>
<thead>
<tr>
<th>Low-Molecular-Weight Iron Dextran(^{15,c})</th>
<th>Ferric Gluconate(^{16,c})</th>
<th>Iron Sucrose(^{17,c})</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Test dose</strong>(^d)</td>
<td>Test dose required: 25 mg slow IV push</td>
<td>Test dose at MD discretion based on risk factors for reaction.</td>
</tr>
<tr>
<td><strong>Dosage</strong>(^{14,e})</td>
<td>100 mg IV over 5 min(^3)</td>
<td>125 mg IV over 60 min(^2,4,5,8)</td>
</tr>
<tr>
<td>- Repeated dosing given once weekly for 10 doses to achieve total dose of 1 g</td>
<td>- Repeated dosing given once weekly for 8 doses</td>
<td>- Repeated dosing given every 2–3 wks or</td>
</tr>
<tr>
<td>or</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Total dose infusion given over several hours(^{18,f})</td>
<td></td>
<td>• Total treatment course = 1000 mg</td>
</tr>
<tr>
<td><strong>Routes</strong></td>
<td>IV infusion</td>
<td>IV injection/infusion</td>
</tr>
<tr>
<td></td>
<td>IM (not recommended)</td>
<td></td>
</tr>
</tbody>
</table>

---

\(^a\) Ferric carboxymaltose has not been prospectively evaluated and therefore should only be considered when other parenteral iron preparations fail.\(^7\) Ferric carboxymaltose is indicated for adult patients when oral iron is not tolerated or there is a limited response. It is also indicated for patients with non-dialysis–dependent chronic kidney disease.\(^11\)

\(^c\) Examples of adverse events associated with FDA-approved doses of parenteral iron preparations include: hypotension, hypertension, nausea, vomiting, diarrhea, pain, fever, dyspnea, pruritus, headaches, and dizziness. Adverse effects associated with low-molecular-weight iron dextran may be delayed 24–48 hours.

\(^d\) Premedications should be given prior to the IV iron test dose as reactions to the test dose may be severe.

\(^e\) For additional details about iron dosing, see prescribing information.

\(^f\) Dose (mL) = 0.0442 (Desired Hgb - Observed Hgb) x LBW + (0.26 X LBW); Dose (mg) = Dose (mL) x 50 mg/mL.

LBW = Lean Body Weight (kg); Hgb = Hemoglobin (g/dL).

If dose exceeds 1000 mg, remaining dose may be given after 4 weeks if inadequate hemoglobin response.

---

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

---

See References ([ANEM-D 3 of 3](#))
NCCN Guidelines Version 2.2017
Cancer- and Chemotherapy-Induced Anemia

PARENTERAL IRON PREPARATIONS1-6 (3 of 3)

REFERENCES

MANAGEMENT OF CANCER- AND CHEMOTHERAPY-INDUCED ANEMIA
FOR PATIENTS WHO REFUSE BLOOD TRANSFUSIONS

• There are limited available data on the best management of cancer- and chemotherapy-induced anemia for patients who refuse blood transfusions.

• In extreme cases of severe, life-threatening anemia, pure oxygen (400 mm Hg, SaO2 = 1.0) has been used to increase blood oxygenation.

• To reduce blood loss, minimize phlebotomy, use pediatric tubes, and batch test.

• Prior to initiation of myelosuppressive chemotherapy:
  ▸ Consider anemia risk when making treatment decisions
  ▸ Consider daily folic acid and B₁₂ supplementation
  ▸ Evaluate and correct baseline coagulation abnormalities
  ▸ In patients with high clinical suspicion of folate and vitamin B₁₂ deficiency, nutritional deficiency should be ruled out and iron deficiency should be corrected using intravenous (IV) iron.

• Consider use of ESAs for select patients by FDA indications/dosing/dosing adjustments, under REMS guidelines, with informed consent of patient.
  ▸ ESAs are NOT recommended for:
    ◊ Patients with cancer not receiving chemotherapy
    ◊ Patients receiving non-myelosuppressive therapy
    ◊ Patients receiving myelosuppressive chemotherapy with curative intent
  ▸ Therefore, if ESAs are prescribed off-label for the indications listed immediately above, patients should be made aware of the potential increased risks of thrombosis and tumor progression, and should know that under these circumstances the ESAs are being used off-label.
  ▸ In addition, prior approval from third-party payers should be sought to prevent increasing the financial burden of the patient.
NCCN Guidelines Version 2.2017
Cancer- and Chemotherapy-Induced Anemia

Discussion

NCCN Categories of Evidence and Consensus

Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

Category 2B: Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.

Category 3: Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.

All recommendations are category 2A unless otherwise noted.

Table of Contents

Overview ...................................................................................... MS-2
Table 1: National Cancer Institute Anemia Scale ......................... MS-2
Literature Search Criteria and Guidelines Update Methodology .... MS-2
Etiology ....................................................................................... MS-3
Anemia Associated with Myelosuppressive Chemotherapy ...... MS-3
Screening Evaluation .................................................................. MS-4
Initial Assessment ....................................................................... MS-4
Approaches to Evaluation .......................................................... MS-4
Table 2: Correction Factor for RPI Calculation ......................... MS-5
Follow-up Risk Assessment ...................................................... MS-6
Red Blood Cell Transfusion ....................................................... MS-6
Benefits of Transfusion ............................................................. MS-7
Risks of Transfusion ................................................................. MS-7
Transfusion Goals and Basic Principles .................................... MS-8
Patients with Cancer Who Refuse Blood Transfusions .......... MS-9
Erythropoietic Therapy ............................................................... MS-9
Benefits of ESA Therapy .......................................................... MS-9
Risks of ESA Therapy ............................................................... MS-10
NCCN Recommendations ..................................................... MS-13
Dosing Schedules .................................................................... MS-14
Response Assessment and Dose Titration .............................. MS-15
Iron Monitoring and Supplementation ..................................... MS-15
Intravenous Iron and Oral Iron ............................................... MS-15
NCCN Evaluation and Definitions of Iron Deficiency .............. MS-18
NCCN Recommendations for the Management of Iron Deficiency .................................................. MS-19
Clinical Examples of Iron Status ............................................. MS-20
Future Development ................................................................. MS-21
References ................................................................................ MS-23
Overview

Anemia is prevalent, occurring in 30% to 90% of patients with cancer.\(^1\) Correction of anemia can be achieved by either treating the underlying etiology or by providing supportive care that may entail transfusion with packed red blood cells (PRBCs) or administration of erythropoiesis-stimulating agents (ESAs), with or without iron supplementation. The first ESA approved by the FDA for the treatment of anemia in patients receiving myelosuppressive chemotherapy was epoetin alfa, a recombinant human erythropoietin (rhEpo). A second-generation rhEpo, darbepoetin alfa, is also FDA approved for this indication.

The pathophysiologic origins of anemia can be grouped into three categories: 1) decreased production of functional red blood cells (RBCs); 2) increased destruction of RBCs; and 3) blood loss. Hence, anemia is characterized by a decrease in hemoglobin (Hb) concentration, RBC count, or hematocrit (Hct) to subnormal levels. The degree of anemia can be graded according to the anemia scale provided by the NCI (Table 1).

### Table 1. National Cancer Institute Anemia Scale

<table>
<thead>
<tr>
<th>Grade</th>
<th>Scale (hemoglobin level in g/dL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 (mild)</td>
<td>10 – lower limit of normal</td>
</tr>
<tr>
<td>2 (moderate)</td>
<td>8 – &lt;10</td>
</tr>
<tr>
<td>3 (severe)</td>
<td>6.5 – &lt;8</td>
</tr>
<tr>
<td>4 (life-threatening)</td>
<td>life-threatening</td>
</tr>
<tr>
<td>5 (death)</td>
<td>death</td>
</tr>
</tbody>
</table>

Source: Adapted from the Common Terminology Criteria for Adverse Events. Available at: [http://evs.nci.nih.gov/ftp1/CTCAE/About.html](http://evs.nci.nih.gov/ftp1/CTCAE/About.html).

The purpose of these NCCN Guidelines is two-fold: 1) to operationalize the evaluation and treatment of anemia in adult patients with cancer, with an emphasis on patients with anemia who are receiving concomitant chemotherapy; and 2) to enable the patient and clinician to assess anemia treatment options in the context of the individual patient condition.

The NCCN Guidelines start with an evaluation of anemia to delineate the etiology. This is followed by a risk assessment to determine the initial intervention plan. Individual patient risk factors and comorbidities may affect the prescribed course of treatment. Further information is provided for treatment options including RBC transfusion, erythropoietic therapy, and iron monitoring and supplementation. These guidelines are mainly focused on patients with solid tumors and lymphoid malignancies. For anemia associated with myelodysplastic syndromes (MDS), myeloid malignancies, and acute lymphoblastic leukemia, clinicians are referred to relevant guidelines listed in the NCCN Guidelines Table of Contents.

### Literature Search Criteria and Guidelines Update Methodology

Prior to the update of this version of the NCCN Guidelines for Cancer and Chemotherapy-Induced Anemia, an electronic search of the PubMed database was performed to obtain key literature published between 03/01/2015 and 03/14/2016, using the following search terms: cancer anemia or cancer-related anemia or cancer-induced anemia or chemotherapy-induced anemia or chemotherapy anemia or chemotherapy-related anemia. The PubMed database was chosen as it remains the most widely used resource for medical literature and indexes only peer-reviewed biomedical literature.\(^2\)
The search results were narrowed by selecting studies in humans published in English. Results were confined to the following article types: Clinical Trial, Phase II; Clinical Trial, Phase III; Clinical Trial, Phase IV; Guideline; Meta-Analysis; Randomized Controlled Trial; Systematic Reviews; and Validation Studies.

The PubMed search resulted in 109 citations and their potential relevance was examined. The data from key PubMed articles as well as articles from additional sources deemed as relevant to these guidelines and discussed by the panel have been included in this version of the Discussion section (eg, e-publications ahead of print, meeting abstracts). Recommendations for which high-level evidence is lacking are based on the panel’s review of lower-level evidence and expert opinion.

The complete details of the Development and Update of the NCCN Guidelines are available on the NCCN webpage.

Etiology

Causes of anemia in patients with cancer are often multifactorial, adding to the complexity of evaluation. Anemia may be attributed to underlying comorbidities such as bleeding, hemolysis, hereditary disease, renal insufficiency, nutritional deficiencies, anemia of chronic disease, or a combination of these factors. The malignancy itself can lead to or exacerbate anemia in a number of ways. Cancer cells may directly suppress hematopoiesis through bone marrow infiltration. They may produce cytokines that lead to iron sequestration, which decreases RBC production and may even shorten RBC survival. Chronic blood loss at tumor sites from blood vessels or organ damage can further exacerbate anemia in patients with cancer. Additional indirect effects may include nutritional deficiencies caused by loss of appetite in patients with cancer, hemolysis by immune-mediated antibodies, or changes in coagulation capability. For this myriad of reasons, anemia is prevalent among patients with cancer at initial presentation. For example, 32% of non-Hodgkin’s lymphoma patients and 49% of patients with gynecologic cancer are anemic at diagnosis. In addition, the myelosuppressive effect of chemotherapy is a significant contributing factor to anemia for patients undergoing cytotoxic treatment. Radiation therapy to the skeleton is associated with hematologic toxicity. In a retrospective analysis, approximately one-third of the 210 patients undergoing craniospinal radiotherapy for treatment of primary tumors of the central nervous system developed grades 3 and 4 hematologic side effects. Newer modalities, including immunotherapy, may also have an associated risk of anemia, though data are limited.

Anemia Associated with Myelosuppressive Chemotherapy

Chemotherapeutic agents induce anemia by directly impairing hematopoiesis in the bone marrow, including disruption of RBC precursor synthesis. Nephrotoxic effects of particular cytotoxic agents (eg, platinum-containing agents) can lead to anemia through decreased production of erythropoietin by the kidney.

Studies have identified patients with lung cancer and gynecologic malignancies as having a very high incidence of chemotherapy-induced anemia (CIA). Platinum-based regimens, commonly used in lung, ovarian, and head and neck cancers, are well known to induce anemia due to the combined bone marrow and kidney toxicity. It is important to review the toxicity profile of each agent as newer regimens may or may not cause anemia. This is evidenced by the comparison of the single agents cabazitaxel, docetaxel, and enzalutamide, which have been shown to cause grade III to IV anemia in 11%, 9%, and 0% of patients, respectively.
The myelosuppressive effects of particular cytotoxic agents are likely to accumulate over the course of repeated cycles of therapy, resulting in a steady increase in the rate and severity of anemia with additional chemotherapy cycles. For example, in the European Cancer Anemia Survey (ECAS), the rate of anemia (Hb level <12 g/dL) was found to increase from 19.5% in cycle 1 to 46.7% by cycle 5. An increase in the fraction of grades 2 to 3 anemia was also associated with a greater number of chemotherapy cycles. Other factors for consideration when evaluating risk for CIA include the nadir Hb level, the time to the nadir Hb level (roughly estimated at 2 weeks, but time can vary), and whether an Hb measurement is considered to be pre- or post-nadir.

Screening Evaluation

Given the wide variation in the Hb level among healthy subjects, a universal “normal” value is difficult to define. For patients with cancer, NCCN Panel Members are in agreement that an Hb level of 11 g/dL or less should prompt an evaluation of anemia. For patients with a high baseline level, a drop of 2 g/dL or more is also cause for concern and assessment. As discussed above, a patient with cancer may suffer from anemia as the result of a combination of causes, some of which may not be directly related to the cancer (reviewed by Gilreath et al). The overall goals of evaluation are to characterize the anemia and identify any potentially correctable underlying comorbidity prior to initiating treatment.

Initial Assessment

Initial broad characterization of anemia involves a complete blood count (CBC) with indices to determine if other cytopenias are present. A visual review of the peripheral blood smear is critical to confirm the size, shape, and Hb content of the RBCs. A detailed history and physical exam must be taken. The history should include the onset and duration of symptoms, comorbidities, family history, and whether there has been any exposure to antineoplastic drugs and radiation. Common complaints are syncope, exercise dyspnea, headache, vertigo, chest pain, fatigue that is disruptive to work and daily activities, and abnormal menstruation in female patients. Pallor may be apparent. A key characteristic distinguishing fatigue related to cancer from fatigue in healthy individuals is that it is less likely to be ameliorated by rest (see NCCN Guidelines for Cancer-Related Fatigue).

The above clinical manifestations are neither sensitive nor specific to the type of anemia. Clinicians should watch out for signs of underlying etiologies such as jaundice, splenic enlargement, neurologic symptoms, blood in the stool, petechiae, and heart murmur, among others.

Approaches to Evaluation

There are two common approaches to evaluating anemia: morphologic and kinetic. A complete evaluation should utilize both. The morphologic approach is a characterization of anemia by the mean corpuscular volume (MCV), or average RBC size, reported in the initial CBC and classified as follows:

- **Microcytic (<80 fL)—**most commonly caused by iron deficiency; other etiologies include thalassemia, anemia of chronic disease, and sideroblastic anemia.

- **Macrocytic (>100 fL)—**most common causes of macrocytosis are medications and alcoholism, both of which are forms of non-megaloblastic anemia. MDS also causes mild macrocytosis. Macrocytosis seen in megaloblastic anemia is most frequently caused by vitamin deficiency resulting from inadequate intake (folic acid) or inadequate absorption from lack of intrinsic factor. Macrocytosis accompanies increased reticulocyte counts following brisk hemorrhage or hemolysis.
• Normocytic (80–100 fL)—may be due to hemorrhage, hemolysis, bone marrow failure, anemia of chronic inflammation, or renal insufficiency. The key follow-up test is the reticulocyte (immature RBC) count (see below).

The kinetic approach focuses on the underlying mechanism of anemia, distinguishing among the production, destruction, and loss of RBCs. The most basic RBC index is the reticulocyte index (RI) that corrects the reticulocyte count against the degree of anemia as measured by Hct. The reticulocyte count, often represented as a percentage, reflects the number of reticulocytes per number of total RBCs. The RI is calculated based on the reticulocyte count and is an indicator of the RBC production capacity by the bone marrow. The normal RI ranges from 1.0 to 2.0.

\[ \text{RI} = \text{Reticulocyte count} \times \left( \frac{(\text{observed Hct})}{(\text{expected Hct})} \right) \]

where the expected Hct is equal to 45%.

Reticulocytes normally persist in the circulation for 24 hours before becoming erythrocytes. However, as anemia increases, younger reticulocytes are released from the marrow requiring them to remain in the circulation for 2 to 3 days before converting to erythrocytes, thereby giving a falsely high value to the RI. The reticulocyte production index (RPI) is an adjusted index that takes this into account and is calculated using the following formula:

\[ \text{RPI} = \text{RI} \times (1/\text{RMT}) \]

where RMT is the reticulocyte maturation time constant determined by the observed Hct (see Table 2).

Table 2: Correction Factor for RPI Calculation

<table>
<thead>
<tr>
<th>Hematocrit (%)</th>
<th>Reticulocyte maturation time (RMT) in days</th>
</tr>
</thead>
<tbody>
<tr>
<td>40–45</td>
<td>1.0</td>
</tr>
<tr>
<td>35–39</td>
<td>1.5</td>
</tr>
<tr>
<td>25–34</td>
<td>2.0</td>
</tr>
<tr>
<td>15–24</td>
<td>2.5</td>
</tr>
<tr>
<td>&lt;15</td>
<td>3.0</td>
</tr>
</tbody>
</table>

A comprehensive review to the follow-up and treatment of each subtype of anemia related to causes independent of myelosuppressive cancer therapy is beyond the scope of this guideline. However, a summary of some additional signs and symptoms of common underlying ailments and/or informative diagnostic tests are as follows:

• Nutritional deficiency—low iron and elevated total iron-binding capacity (TIBC) and/or low vitamin B12 or red cell folate levels (commonly tested together with iron studies). Ferritin values are also useful in evaluating iron stores. Fasting values are preferred for iron studies.

• Hemorrhage—stool guaiac positive, endoscopy findings

• Hemolysis—Direct antiglobulin test positive, disseminated intravascular coagulation panel positive, low haptoglobin levels,
NCCN Guidelines Version 2.2017
Cancer- and Chemotherapy-Induced Anemia

- Elevated indirect bilirubin, elevated lactate dehydrogenase (LDH)
- Renal dysfunction—glomerular filtration rate less than 60 mL/min/1.73 m² for three or more consecutive months
- Inherited anemia—personal and family history
- Sideroblastic anemia—sideroblasts present in bone marrow biopsy

Clinicians are advised to consult the section Iron Monitoring and Supplementation for details on management of iron deficiency. Any other cause of anemia that may be rectified independent of cancer therapy should be treated as indicated. When no such etiology is identified, the effects of cancer-related inflammation and/or myelosuppressive chemotherapy (if applicable) should be considered the cause of anemia.

Follow-up Risk Assessment

If the likely cause of anemia is cancer-related inflammation and/or myelosuppressive chemotherapy (for solid tumors or lymphoid malignancies), a risk assessment of the anemia is necessary to determine the initial intervention plan. The decision regarding the best treatment is dependent on many factors. While PRBC transfusion is the only option if the patient requires an immediate boost in Hb levels, consideration of ESA therapy and iron supplementation is warranted for the long-term management of anemia as determined by risk assessment.

Red Blood Cell Transfusion

When considering the decision to offer PRBC transfusion, it should not be made on the basis of whether the Hb level of the patient has reached a certain threshold or “trigger.” Instead, the NCCN Panel outlines three general categories: 1) asymptomatic without significant comorbidities, for which observation and periodic re-evaluation are appropriate; 2) high risk (ie, progressive decline in Hb with recent intensive chemotherapy or radiation) or asymptomatic with comorbidities (eg, cardiac disease, chronic pulmonary disease, cerebral vascular disease), for which transfusion should be considered; and 3) symptomatic, for which patients should receive transfusion.

The clinical manifestations of anemia are associated with the onset, severity, and duration of the anemia, as well as other factors influencing tissue demands for oxygen. When anemia onset is acute, symptoms are likely to be more pronounced, whereas physiologic adjustments to compensate for the lower oxygen-carrying capacity of the blood can occur with the gradual onset of anemia. These adaptive measures include heightened cardiac output, increased coronary flow, altered blood viscosity, and changes in oxygen consumption and extraction. The presence of preexisting cardiovascular, pulmonary, or cerebral vascular disease may compromise the ability of a patient to tolerate anemia. Hence, decisions related to whether immediate correction of anemia is needed must be based on an assessment of individual patient characteristics, severity of anemia, presence and severity of comorbidities, and the clinical judgment of the physician. For example, even when an anemic patient has no physiologic symptoms or significant comorbidity, transfusion may be appropriate if there is an anticipated progressive decline in Hb level following anti-cancer treatment.
PRBCs are the blood product of choice for transfusion to correct anemia. These are concentrated from centrifuged whole blood donations or collected by apheresis. They are anticoagulated and may contain added preservatives. Further enhancements include leuko-reductions, γ-irradiation, freezing, and washing. Patients who are immunocompromised may need PRBCs that are cytomegalovirus negative. One unit of PRBCs (300 cc) can have an Hct ranging from 50% to 80%, and typically contains 42.5 to 80 g of Hb (with 147–278 mg of iron) or 128 to 240 mL of pure RBCs.  

**Benefits of Transfusion**

The major benefit of transfusion with PRBCs, offered by no other treatment of anemia, is a rapid increase in Hb and Hct levels. Hence, PRBC transfusion is the only option for patients who require immediate correction of anemia. Transfusion of 1 unit (300 cc) of PRBCs has been estimated to result in an average increase in Hb level of 1 g/dL or in Hct by 3% in a normal-size adult who is not experiencing a simultaneous loss of blood.  

It should be noted that patients receiving concomitant fluid resuscitation may not experience an Hb increase of 1 g/dL per unit of blood transfused.

Results from a number of studies evaluating the impact of transfusion on mortality in patients with cancer have been conflicting, with some studies showing a survival benefit for patients receiving transfusion. For example, in a study of 56 consecutive patients with unresectable esophageal cancer receiving chemoradiation therapy, blood transfusion was associated with an increase in overall survival (OS) (hazard ratio [HR], 0.26; 95% CI, 0.09–0.75, P = .01).  

A retrospective study of data collected from 605 patients with carcinoma of the cervix evaluated Hb levels prior to therapy through completion of therapy. Patients with high Hb levels prior to therapy had a significant increase in disease-free survival and OS. Patients who were transfused to increase Hb levels had a survival rate that was similar to patients who had the same initial Hb value but did not receive transfusion. Data suggest that blood transfusion reduced the negative prognostic implication of low Hb.

**Risks of Transfusion**

Risks associated with PRBC transfusion include transfusion-related reactions, transfusion-associated circulatory overload, bacterial contamination and viral infections, iron overload (reviewed by Spivak, Gascon, and Ludwig), and alloimmunization of RBCs or platelets. Since 1984, the introduction of numerous safety interventions to screen the U.S. blood supply for infectious organisms has dramatically decreased the risk of transfusion-transmitted infections. Bacterial infection is the most common form, and occurred as frequently as 1 in 3000 random-donor samples before the mandate of bacterial screening in 2004. Since the implementation of screening, fewer than 10 deaths from bacterial sepsis per year have been reported. Pre-storage leukoreduction has been shown to decrease the incidence of febrile non-hemolytic transfusion reactions, the most common adverse reaction.

Khorana et al analyzed data from discharge summaries of patients with cancer admitted to 60 U.S. medical centers between 1995 and 2003 and found increased risks (P < .001) of venous thromboembolism (VTE) (overall risk [OR], 1.60; 95% CI, 1.53–1.67), arterial thromboembolism (OR, 1.53; 95% CI, 1.46–1.61), and in-hospital mortality (OR, 1.34; 95% CI, 1.29–1.38) associated with PRBC transfusions. However, the increased thrombotic events and decreased survival may reflect a bias of more severe anemia and/or more advanced cancer in patients who require transfusions. A cause-effect relationship could not be established due to the retrospective

nature of the study. Therefore, greater investigation into the relationship between blood transfusions and the incidence of VTE and mortality is warranted.

RBC alloimmunization can be a significant complication for patients who are chronically transfused. It has been reported that 15% of transfusion-dependent patients with MDS or chronic myelomonocytic leukemia have alloimmunization. Platelet alloimmunization may also occur. Antibodies against HLA antigens can cause platelet transfusion refractoriness, which can translate into increased patient bleeding, prolonged hospitalization, and decreased survival.

Iron Overload

The condition of transfusion-related iron overload is observed in patients requiring frequent transfusions over several years to manage their anemia (eg, patients with MDS). However, iron overload is unlikely to occur in patients receiving transfusions that are limited to the time period corresponding to chemotherapy treatment (usually <1 year). As previously mentioned, each transfusion of PRBCs contains 147 to 278 mg of unexcretable excess iron. When iron stores become saturated, iron remains as non-transferrin–bound iron. Typically after 10 to 15 transfusions of PRBCs, excess iron will have deposited in the liver, heart, skin, and endocrine organs. Patients experiencing iron overload may present with fatigue, dark skin, arthralgia, hepatomegaly, cardiomyopathy, or endocrine disorders. Benefits of PRBC transfusion need to be weighed against cumulative cardiac and hepatic toxicity.

Serum ferritin levels and any associated end-organ dysfunction need to be monitored in patients requiring chronic PRBC transfusions. While a survival benefit to chelation therapy has not been shown in patients requiring transfusion support for cancer-induced anemia or MDS, the general target value is a ferritin level of less than 800 mcg/L. Imaging modalities such as FerriScan and T2 star-weighted cardiac MRI provide useful organ-specific iron overload assessment.

Transfusion Goals and Basic Principles

There is wide variation in reported PRBC transfusion practice, but institutional and clinical practice guidelines are often "restrictive" regarding limiting exposure to allogeneic blood. The overall goal of transfusion is to treat or prevent the deficiencies in the oxygen-carrying capacity of the blood, in order to improve oxygen delivery to body tissues. Transfusion is rarely indicated when the Hb level is above 10 g/dL. The AABB (formerly the American Association of Blood Banks) published guidelines based on a systematic review of randomized trials evaluating transfusion thresholds and using GRADE guidelines methodology. AABB recommendations include: 1) using an Hb level of 7 g/dL as a threshold for hospitalized patients who are hemodynamically stable; 2) considering transfusions for hospitalized patients with pre-existing cardiovascular disease who have symptoms and an Hb level of 8 g/dL or less; and 3) making transfusion decisions for all patients based on symptoms as well as Hb levels. There was a lack of evidence to provide specific recommendations for the cancer population. During NCCN panel discussion, concerns were raised regarding the implications of current ESA restrictions on the transfusion burden. Panelists agree that no single target Hb level is appropriate for all cases and that the balance between risks and benefits should be evaluated on an individual basis. Clinicians are urged to exercise their clinical judgment based on patient symptoms, cancer course and treatment, comorbidities, and patient preference.

Prior to transfusion, PRBCs must be crossmatched to confirm compatibility with ABO and other antibodies in the recipient. There is no evidence to support routine premedication with acetaminophen or an...
antihistamine to prevent allergic and febrile nonhemolytic transfusion reactions. However, if repeated transfusions are required, leukocyte-reduced blood, and the use of premedication may minimize adverse transfusion reactions. In most instances, PRBCs should be transfused by the unit, and reassessment should be conducted after each transfusion.

Patients with Cancer Who Refuse Blood Transfusions
Patients with cancer who refuse blood transfusions are occasionally seen in clinical practice. Their religious beliefs or personal preferences prohibit them from using blood products in their treatment, so clinicians who agree to treat these patients must base treatment on limited available data. However, several strategies may be employed to reduce anemia. For example, intensive myelosuppressive chemotherapy would induce symptomatic anemia in most patients with cancer, but investigators have outlined strategies to permit such treatment to be given without transfusion. Strategies include minimizing blood loss by restricting and/or batching routine laboratory testing, using pediatric blood collection tubes, using anti-fibrinolytic drugs for oral bleeding, aggressively treating mucositis, suppressing menses, and minimizing gastrointestinal bleeding by using proton pump inhibitors and stool softeners.

Baseline coagulation abnormalities should be fully evaluated and corrected prior to myelosuppressive treatment. Nutritional deficiencies have a low prevalence in both the general population and in patients with cancer. However, in patients with high clinical suspicion of folate and vitamin B12 deficiency, nutritional deficiency should be ruled out and iron deficiency should be corrected using intravenous (IV) iron. ESAs may be offered; however, prior approval from third-party payers should be sought to prevent increasing the financial burden of the patient. Patients should also be made aware of the potential increased risks of thrombosis and tumor progression, and should know that under these circumstances the drugs are being used off-label. ESAs should only be considered for select patients and are not recommended for the following: 1) patients with cancer who are not receiving chemotherapy; 2) patients receiving non-myelosuppressive therapy; or 3) patients receiving myelosuppressive chemotherapy with curative intent. Lastly, in extreme cases with severe, life-threatening anemia, pure oxygen (400 mmHg, $S_O^2 = 1.0$) has been used to increase blood oxygenation.

Erythropoietic Therapy
RBC production is normally controlled by erythropoietin, a cytokine produced in the kidneys. ESAs have been shown to stimulate erythropoiesis in patients with low RBC levels, though not all patients have disease that responds to ESA therapy. In a study of 2192 patients with cancer receiving ESA therapy, an Hb increase of greater than or equal to 1 g/dL was attained in 65% of patients. Unlike transfusion that immediately boosts the Hb level, ESAs can take weeks to elicit an Hb response, but they are effective at maintaining a target Hb level with repeated administration.

Benefits of ESA Therapy
Elimination of symptoms and avoidance of transfusion are the main goals of ESAs. ESA therapy has been demonstrated to decrease PRBC transfusion requirements in patients with cancer undergoing chemotherapy. In a randomized, placebo-controlled study by Littlewood and colleagues, epoetin alfa was shown to reduce transfusion requirements in patients with anemia receiving chemotherapy compared with placebo (24.7% vs. 39.5%, $P = .0057$), and the Hb level was increased (2.2 g/dL vs. 0.5 g/dL, respectively; $P < .001$). A double

blind, placebo-controlled, randomized phase III study enrolled 320 patients (Hb ≤11 g/dL) receiving darbepoeitn alfa at 2.25 mcg/kg/wk versus placebo.52 Patients receiving darbepoeitn alfa required fewer transfusions (27% vs. 52%; 95% CI, 14%–36%; P < .001) than patients receiving placebo. The ability of ESAs to reduce transfusions was one endpoint used in a Cochrane review that enrolled a total of 20,102 patients undergoing treatment for cancer with concomitant ESA therapy.53 A decreased relative risk (RR) for transfusion was observed in patients receiving erythropoeitn (RR, 0.65; 95% CI, 0.62–0.68).53 Of the patients treated with ESAs, 25 out of 100 subsequently received a transfusion versus 39 out of 100 patients in the untreated group, equating to a one-unit reduction in transfusion in ESA-treated patients.

Risks of ESA Therapy

Risk for Thromboembolism

Increased thromboembolic risks have been associated with ESA treatment of patients with cancer. The cause of VTE is complex with a heightened baseline risk related to both the malignancy itself and to chemotherapy (see NCCN Guidelines for Venous Thromboembolic Disease).54-57 Other risk factors for VTE in patients with cancer include prior history of VTE, inherited or acquired mutations, hypercoagulability, elevated pre-chemotherapy platelet counts, recent surgery, hormonal agents, immobility, steroids, and comorbidities such as hypertension.58 Results from meta-analyses established a significant association between increased risk of thrombotic events and ESA usage, with statistically significant risk and odds ratios ranging from 1.48 to 1.69.53,59-63 A combined analysis of six trials using darbepoeitn alfa by Glaspy and colleagues64 also found an increased trend of thromboembolism for patients with Hb greater than 12 g/dL (RR, 1.66; 95% CI, 0.9–3.04) or in patients achieving a greater than 1 g/dL increase in 14 days (RR, 1.67; 95% CI, 0.96–2.88). An increased risk of stroke was associated with darbepoeitn alfa in a clinical trial of patients with chronic kidney disease (CKD) (HR, 1.92; 95% CI, 1.38–2.68).65 Furthermore, in a retrospective case-controlled study of CKD patients with cancer, ESA use was associated with a significantly increased risk of stroke (OR, 1.83; 95% CI, 1.26–2.65).66 The increased risk for thromboembolism in patients with cancer receiving ESA therapy is specified in the black-box warnings included in FDA labels. The NCCN Panel cautions physicians to be alert of the signs and symptoms of thromboembolism in patients with cancer receiving ESAs.

A randomized phase III study comparing epoetin versus best supportive care for the treatment of anemia in women with metastatic breast cancer (n = 2098) reported similar progression-free survival, median OS, time to tumor progression, and overall response rates between the two groups.67 There was a reduction in the number of RBC transfusions in the epoetin-treated patients compared to patients receiving best supportive care (5.8% vs. 11.4%; P = .038); however, the rate of thrombotic vascular events was higher (2.8% vs. 1.4%, respectively; P = .038). Taken together, non-inferiority of epoetin was not established, and transfusions remained the preferred treatment for anemia in patients with metastatic breast cancer.

Possible Increased Mortality and Tumor Progression

Since 2007, the FDA has made substantial revisions to the label information and regulations regarding epoetin alfa and darbepoeitn alfa,68,69 including the addition of a black box label warning and implementation of a risk management program known as Risk Evaluation and Mitigation Strategy (see REMS: Risk Evaluation and Mitigation Strategy for Erythropoeis Stimulating Agents (ESAs) in the algorithm). The strengthened FDA restrictions were mainly based on the results of 8 randomized studies that individually showed a decrease in OS and/or decreased locoregional disease control with ESA usage in...
advanced breast, cervical, head and neck, lymphoid, and non-small cell lung cancers.\textsuperscript{70-77} Of the 8 studies, four studies investigated ESA effects in patients who underwent chemotherapy, 2 studies were in patients receiving radiotherapy alone, and 2 studies were in patients receiving neither chemotherapy nor radiotherapy. All 8 trials had an off-label target Hb level over 12 g/dL.

Worsened health outcomes associated with the use of ESAs have been observed in 5 meta-analyses of 51 to 91 randomized controlled trials when targeting Hb levels above 12 g/dL.\textsuperscript{53,59,61,63,78,79} These analyses reported increased mortality in patients receiving ESAs with statistically significant RR/HR of 1.17 (95% CI, 1.06–1.30),\textsuperscript{16} 1.15 (95% CI, 1.03–1.29),\textsuperscript{63} 1.10 (95% CI, 1.01–1.20),\textsuperscript{59} 1.17 (95% CI, 1.06–1.29),\textsuperscript{53} and 1.17 (95% CI, 1.04–1.31).\textsuperscript{61} Data from the Cochrane Database reported increased mortality in patients with Hb over 12 g/dL that also associated with patients who did not receive concurrent therapy.\textsuperscript{53} This suggests that increased mortality could be reduced by more conservative target Hb levels. In keeping with current treatment practice, data from a systematic review by the Agency for Healthcare Research and Quality (AHRQ) determined that delaying ESA treatment until Hb is less than 10 g/dL resulted in fewer thromboembolic events and a reduced mortality. However, the difference with early treatment was not significant, and optimal duration of therapy could not be determined from the limited data.\textsuperscript{61}

The association between increased mortality and ESA therapy has been debated in other meta-analyses, including two studies reporting no statistically significant effect of ESAs on mortality or progression based on HR/odds ratios of 0.97 (95% CI, 0.85–1.1)\textsuperscript{62} and 1.06 (95% CI, 0.97–1.15).\textsuperscript{60} Trials with off-label use of rhEpo, in both the adjuvant and neoadjuvant setting, reported no decrease in survival with ESA use in patients with chemotherapy-related anemia when an Hb target of 13 g/dL was utilized.\textsuperscript{80-82} The PREPARE trial found no difference in the 3-year OS (darbepoetin alfa, 88.4\% vs. no darbepoetin alfa, 91.5\%; HR, 1.26; 95\% CI, 0.86–1.85; \textit{P} = .237), though there was a trend towards decreased disease-free survival that failed to reach statistical significance (darbepoetin alfa, 74.3\% vs. no darbepoetin alfa, 80.0\%; HR, 1.31; 95\% CI, 0.999–1.74; \textit{P} = .061).\textsuperscript{82,83} The phase III WSG-ARA trial that included 1234 patients with early-stage breast cancer treated with adjuvant ESA is the first to evaluate survival as the primary endpoint.\textsuperscript{84} In this study, no impact on EFS (darbepoetin alfa, 89.3\% vs. no darbepoetin alfa, 87.5\%; \textit{P}_{log-rank} = 0.55) or OS (darbepoetin alfa, 95.5\% vs. no darbepoetin alfa, 95.4\%; \textit{P}_{log-rank} = 0.77) was observed. There was an increase in venous thrombosis with darbepoetin alfa (darbepoetin alfa, 3\% vs. no darbepoetin alfa, 1\%; \textit{P} = .013), though no increase was seen for pulmonary embolism (0.3\%, both groups). The incidence of grade 2 anemia was higher in patients who were not treated with darbepoetin alfa (darbepoetin, 10.9\% vs. no darbepoetin, 23.8\%; \textit{P} = .025). Results suggest that the value of darbepoetin alfa may be dependent on other risk factors, including patient comorbidities, type of cancer, and type of treatment intent. It should be noted that ESAs are not recommended for patients treated with curative intent outside of a clinical trial. There are also data from randomized studies that show no increase in mortality in patients receiving chemotherapy for small cell lung cancer (SCLC) when ESAs are given according to the prescribing label.\textsuperscript{85,86}

A meta-analysis of three randomized, placebo-controlled trials in Japanese patients with CIA did not show an increased mortality associated with the use of ESAs.\textsuperscript{87} In this study, 511 patients with either a solid tumor or lymphoma were treated with epoetin beta or darbepoetin alfa. The efficacy endpoints in this study included PRBC
transfusion and transfusion trigger (ie, transfusion or Hb below 8 g/dL) from week 5 until the end of treatment. Safety endpoints were determined by OS and thromboembolic events. The risk of transfusion was reduced by 53% with ESA treatment compared to the placebo group (RR, 0.47; 95% CI, 0.29–0.76), while OS was equivalent (HR, 1.00; 95% CI, 0.75–1.34; median, 13.3 months). The rates of thromboembolic events were 0.7% in the ESA-treated patients and 1.7% in the placebo group (P = NS; no deaths). The study authors highlight several differences between this study and the Cochrane Database report. The first is the time period in which these trials were conducted. The recent analysis included trials occurring between 2006 and 2009, during which there was awareness of the possible association between ESA use and increased mortality. Therefore, patients were likely to have greater supervision as indicated by the requirement of Hb monitoring at least weekly and the establishment of pre-determined cut-off values for the discontinuation of ESAs. Furthermore, only CIA patients were included in the three Japanese studies. In addition to equivalent OS, quality of life measured in terms of patient-reported fatigue was improved with ESA treatment.

Possible Increased Fatigue
A recent systematic review and meta-analysis evaluated the effects of ESAs on fatigue and anemia-related symptoms. The study included 37 randomized controlled trials with a total of 10,581 patients. The evaluation of fatigue was based on determining a clinically important difference (CID) on either the FACT-Anemia or FACT-Fatigue scale. Fatigue evaluation was below the threshold for CID established at greater than or equal to 3 (CID = 2.14; 95% CI, 1.39–3.43). However, the FACT-Anemia scale showed a CID above the threshold set at 4 (CID = 4.09; 95% CI, 2.37–5.80; P = .001). These results suggest that ESAs provide a small but clinically important improvement in anemia-related symptoms in patients with cancer, particularly those receiving chemotherapy.

Risk for Hypertension/Seizures
Seizures have been reported in patients with chronic renal failure receiving ESAs. There is a 2.5% incidence of seizure in patients on dialysis during the first 90 days of therapy. While it is unclear whether patients with cancer receiving ESA therapy are at risk for seizures, Hb levels should be monitored before and during the use of ESAs to decrease the risk for these adverse events. An increased risk for hypertension with ESA usage was reported by a Cochrane review (RR, 1.30; 95% CI, 1.08–1.56).

Risk for Pure Red Cell Aplasia
Pure red cell aplasia (PRCA) is a rare syndrome of anemia characterized by a low reticulocyte count and loss of bone marrow erythroblasts caused by the development of neutralizing antibodies against erythropoietin. From 1998 to 2004, however, a marked rise in incidence (191 cases) was observed, though 90% of cases occurred with an epoetin alfa product used outside of the United States. Causation was attributed to formulations without human serum albumin, subcutaneous (SC) administration, and uncoated rubber stoppers. Interventions, designed accordingly, reduced the incidence of PRCA by 83%. In 2005, the FDA interpretation of anemia associated with neutralizing antibodies evolved to include both PRCA and severe anemia, with or without other cytopenias, associated with neutralizing antibodies, resulting in a class label change for all ESAs. This toxicity has been reported predominantly in patients with chronic renal failure receiving SC ESAs.
NCCN Recommendations

To promote safety, the FDA requires that ESAs only be administered with informed patient consent under the REMS program for patients with cancer. The REMS program (https://www.esa-apprise.com/ESAAppriseUI/) consists of Medication Guides for patients and the ESA APPRISE (Assisting Providers and Cancer Patients with Risk Information for the Safe Use of ESAs) program for prescribing physicians (see REMS: Risk Evaluation and Mitigation Strategy for Erythropoiesis Stimulating Agents (ESAs) in the algorithm). Although the ESA APPRISE program does not apply to patients with cancer who are receiving ESA therapy for CKD, the panel still recommends that clinicians adhere to this program.

For patients with cancer, the black box warning on the revised FDA label states that ESAs should only be used to treat CIA and should be discontinued once the chemotherapy course is complete. As discussed previously, randomized trial data suggest that ESAs may promote tumor growth in an off-target manner. For this reason, the FDA states that these agents should not be used when the anticipated treatment outcome is cure. This includes primary and adjuvant chemotherapy for malignancies such as early-stage breast cancer and non-SCLC, lymphomas, and testicular cancer, among others. An exception to this may be SCLC, for which there are trials demonstrating no negative impact on survival or disease progression (see earlier discussion). Hence, patients not receiving concomitant myelosuppressive chemotherapy are not eligible. Additionally, ESAs are not recommended for patients who are not receiving therapy or for patients on non-myelosuppressive therapy. Patients undergoing palliative treatment may consider ESA or transfusion therapy depending on their preferences and personal values. The NCCN Guidelines Panel recognizes that it is not always clear whether a chemotherapy regimen is considered curative. Under these circumstances, given that no other cause of anemia has been identified, anemia management should first consider PRBC transfusion or clinical trial enrollment if available. Upon the decision to use an ESA, physicians are advised to use the lowest dose necessary to eliminate symptoms and avoid transfusion.

CKD is an independent indication for ESA therapy. Adverse events occurring with the use of ESAs in these patients appear to be associated with high doses and/or high-target Hb levels, and the FDA label mandates individualized dosing to reduce the need for RBC transfusions. Controlled clinical trials have associated increased risk of mortality and adverse cardiovascular outcomes with ESAs in CKD patients when targeted to Hb levels over 11 g/dL. In the study by Pfeffer et al (comparing darbepoetin alfa to placebo), a statistically significant increase in death due to cancer was seen in CKD patients who had pre-existing cancer at baseline (P = .002). Conversely, in a study of patients with CKD stages 4 and 5, an increased incidence in cancer was not observed, and it is highlighted that the average Hb was 10.1 g/dL. Data from Seliger and colleagues indicated that ESA treatment in patients with CKD was not associated with an overall increased risk for stroke except in the subpopulation diagnosed with cancer. Since almost one-third of patients with end-stage renal disease are also afflicted with cancer, they represent a unique group that requires personalized use of ESAs based on very careful evaluation of risks and benefits (reviewed by Bennett et al). For example, CKD patients not receiving active therapy for a malignancy should try to avoid ESAs, while those receiving palliative chemotherapy may favor carefully dosed ESAs over transfusions to treat severe anemia. In the scenario where the patient with CKD has a curable solid tumor, ESAs should not be administered during chemotherapy. However, they may be used with caution after chemotherapy is...
complete, keeping in mind the possibility of residual disease. Risk for thrombosis must be taken into account as part of the risk-benefit ratio.

Most hematopoietic cell transplant patients require transfusion support. Nonetheless, ESA therapy may be useful in some instances. For example, ESAs may be administered post-transplant to increase the Hct in order to allow phlebotomy to treat transfusional iron overload. There have been reports of ESA efficacy in patients who refuse blood transfusions while undergoing autologous cell transplantation.

Post-transplant use of ESAs for patients undergoing cancer chemotherapy, patients with renal insufficiency, or patients with recurrent/secondary MDS should follow guidelines for chemotherapy-related anemia, CKD, or MDS, respectively.

Iron studies should accompany ESA therapy to monitor the development of iron deficiency. These include serum iron, TIBC, and serum ferritin. The NCCN Panel recommends that any patient with cancer who develops a sudden loss of response to ESAs, accompanied by severe anemia and a low reticulocyte count, should be evaluated for the etiology of loss of effect. ESAs should be withheld while plasma is sent to ESA-manufacturing pharmaceutical companies for evaluation by assays that measure binding and neutralizing antibodies to erythropoietin. ESAs should be discontinued in patients with antibody-mediated anemia. Patients should not be switched to other ESA products as antibodies may cross-react.

Dosing Schedules

Epoetin alfa and darbepoetin alfa are considered equivalent by the NCCN Panel. Recommended initial dosing schedules for patients receiving chemotherapy are summarized in the algorithm. The most common initial dosing schedules for epoetin alfa evaluated in clinical trials of patients with cancer are 150 units/kg three times weekly administered SC and 40,000 units administered once weekly SC (see Erythropoietic Therapy – Dosing, Titration, and Adverse Effects in the algorithm). Both of these initial dose schedules are listed in the package insert and are recommended by NCCN. Other dosing ranges and schedules of epoetin alfa may be considered, including an extended dosing of 80,000 units SC every 2 weeks and a dose of 120,000 units SC once every 3 weeks.

Although darbepoetin alfa doses were initially administered at 2.25 mcg/kg SC every week, there has been interest in either fixed doses or higher doses at decreased frequency. A randomized trial compared weekly dosing at 2.25 mcg/kg versus fixed dosing at 500 mcg every three weeks in 705 patients with non-myeloid malignancies and an Hb level below 11 g/dL. The percentage of patients achieving the target Hb level (≥11 g/dL) was 77% in the weekly arm and 84% for patients receiving darbepoetin alfa every three weeks. Both of these schedules are listed in the package insert. Dosing once every three weeks was further refined in two studies by reducing the dose to 300 mcg. Initially, a multicenter, open-label study of 1493 patients showed that 79% of patients achieved a target Hb level greater than or equal to 11 g/dL. A head-to-head comparison with 500 mcg in a phase II, randomized study of patients with nonmyeloid malignancies further confirmed the efficacy of 300 mcg. In this study, patients were given either 300 or 500 mcg of darbepoetin alfa with or without concurrent iron therapy. No difference in the proportion of patients who achieved target Hb levels (≥11 g/dL) was seen between those receiving 300 mcg versus 500 mcg darbepoetin alfa (75% vs. 78%, respectively). Other studies have demonstrated the safety and efficacy of alternative dosing schedules for darbepoetin alfa. These include a fixed weekly dose of 100 mcg and a fixed dose of 200 mcg every 2 weeks. In addition to the dosing schedule on the package insert, the NCCN Panel...
recommends these alternative regimens to aim for the smallest yet still effective dose.

**Response Assessment and Dose Titration**

Response to ESA therapy is assessed to determine whether the initial dose should be reduced, escalated, or withheld. Decisions related to ESA dose adjustment are based on the goal of a gradual increase in Hb level that remains sufficient to avoid transfusion.

ESAs require at least 2 weeks of treatment before there is an increase in the number of RBCs. Hb level should be measured weekly until stabilized. Dose reduction (generally 25%–40%) should be implemented if the Hb level increases by 1 g/dL or more during a 2-week period, or if Hb reaches a level sufficient to avoid transfusion.

Conversely, the ESA dose should be increased according to the algorithm (see *Erythropoietic Therapy – Dosing, Titration, and Adverse Effects* in the algorithm) for patients receiving chemotherapy who show no response (<1 g/dL Hb increase) following 4 weeks of epoetin alfa or 6 weeks of darbepoetin alfa. Iron supplementation can be considered to improve response to ESA therapy. A subsequent response at 8 or 9 weeks for patients on ESA dosing schedules of every 2 or 3 weeks may necessitate a dose titration to avoid transfusion. Individuals receiving weekly doses of ESA therapy can be evaluated for subsequent response at 8 or 9 weeks. The same dose reduction formulas as described above should be followed. ESA therapy should be discontinued in patients showing no response despite iron supplementation after 8 or 9 weeks of therapy, and PRBC transfusion should be considered. ESAs should be discontinued when the chemotherapy cycle is complete or when chemotherapy is discontinued.

**Iron Monitoring and Supplementation**

**Intravenous Iron and Oral Iron**

Iron can be administered in oral form or parenteral form (low-molecular-weight iron dextran, ferric gluconate, and iron sucrose). Evidence from 5 published studies utilizing iron in conjunction with an ESA suggest that IV iron is superior to oral iron. Eligibility criteria for these trials varied widely (serum ferritin requirement ranging from >10 ng/mL to <900 ng/mL and a TSAT level requirement ranging from >15% to <60%). Only one study provided guidelines for TSAT monitoring, while two studies provided guidelines for ferritin monitoring.

A recent randomized controlled trial comparing the efficacy of IV iron sucrose versus oral ferrous fumarate in patients with gynecologic cancer (N = 64) evaluated the use of IV iron monotherapy for the “primary prevention” of anemia (ie, patients did not have presenting anemia). Previously, IV iron was shown to be effective in the treatment of patients with anemia who had a prior blood transfusion. In this study, patients were given a single dose of 200 mg iron sucrose following each course of chemotherapy infusion for 6 cycles. The number of patients requiring blood transfusion was double in the oral iron group compared to the IV iron group (56.3% vs. 28.1%; P = .02). Furthermore, patients receiving IV iron required transfusion for a fewer number of cycles versus the oral iron group (0 vs. 0.5 cycle; P = .04) with fewer total units of PRBCs (0 vs. 0.5 units; P = .05). Neither group experienced hypersensitivity reactions or other serious adverse events. However, constipation occurred in a greater percentage of patients in the control group compared to the IV iron group (40.6% vs. 3.1%; P < .001).

A prospective, multicenter, open-label trial randomized 157 patients with CIA receiving epoetin alfa to: 1) no iron; 2) oral iron; 3) iron dextran IV
bolus; or 4) iron dextran total dose infusion (TDI). Increases in Hb concentration were greater with IV iron (groups 3 and 4) compared to oral supplementation or no iron ($P < .02$), while there was no difference between the oral and no iron groups ($P = .21$). Additionally, there was no statistically significant difference between groups 3 and 4 ($P = .53$), suggesting that lower, intermittent doses of IV iron are equally as efficacious as TDI. In a second open-label study by Henry and colleagues, 115 187 anemic patients with cancer receiving chemotherapy and epoetin alfa were randomized to no iron, oral ferrous sulfate three times daily, or weekly IV ferric gluconate. The Hb response rate ($\geq 2$ g/dL increase) was higher in the IV arm (73%) compared to the oral (45%) or no iron (41%) arms. A third study enrolled 67 patients with lymphoproliferative malignancies not undergoing chemotherapy. 114 Patients were randomized to weekly epoetin beta with or without IV iron sucrose. Although an oral iron arm was not included, IV iron resulted in a higher mean change in Hb level from baseline (2.76 g/dL vs. 1.56 g/dL, $P = .0002$) and a higher Hb level response rate ($\geq 2$ g/dL increase; 87% vs. 53%, $P = .0014$) compared to the no iron arm.

Two additional studies were published in 2008. Bastit et al reported their open-label trial evaluating 396 patients with nonmyeloid malignancies undergoing chemotherapy (Hb $< 11$ g/dL). 113 Patients were treated with darbepoetin alfa with or without IV iron (iron sucrose or ferric gluconate 200 mg every three weeks for 16 weeks). Erythropoietic responses and time to reach the target Hb level were better in the IV iron arm. Most significantly, this was the first study to associate IV iron with fewer RBC transfusions in patients with cancer (9% vs. 20%, $P = .005$). In a study by Pedrazzoli et al, 116 149 patients with solid tumors and CIA were randomly assigned to receive weekly darbepoetin alfa with or without ferric gluconate. This was the first trial that excluded patients with absolute iron deficiency; eligibility requirements included a serum ferritin level greater than 100 ng/mL and a TSAT level greater than or equal to 20%. The ESA/IV iron group showed a higher hematopoietic response rate compared to the control group (93% vs. 70%, respectively; $P = .0033$). Taken together, these studies demonstrated that concurrent IV iron enhanced hematologic response to ESAs. There is insufficient evidence to determine whether iron supplementation can allow for an ESA dose decrease. Long-term effects of IV iron supplementation in patients with cancer were not assessed in any of these five trials.

In 2011, Steensma et al published findings from the largest trial to date that challenged these positive results. Roughly 500 patients with CIA were randomized 1:1:1 to IV ferric gluconate, oral ferrous sulfate, or oral placebo. IV iron failed to confer benefit in terms of Hb response, transfusion rate, or quality of life compared to oral iron or placebo. One possibility for the lack of response may be that the mean baseline TSAT level for patients in the IV iron group was 22.5%, a value above what is considered to be associated with functional iron deficiency.

A systematic review and meta-analysis evaluating the role of iron supplementation has been reported. 119 Eleven randomized controlled trials analyzed IV iron versus standard of care in patients with CIA. Nine trials incorporated ESAs into treatment, 3 trials compared IV iron to oral iron as the standard of care, and 6 trials compared IV iron to no iron. IV iron supplementation versus no iron in patients treated with ESAs showed a significantly higher rate of hematopoietic response ($n = 7$ trials; RR, 1.28; 95% CI, 1.125–1.45; $I^2 = 68.1%$; random effects model) and significantly reduced transfusion rates compared to standard of care ($n = 7$ trials; RR, 0.76; 95% CI, 0.61–0.95). Reduction in the number of blood transfusions was also seen in the two trials without ESAs (RR, 0.52; 95% CI, 0.34–0.80). IV iron was superior to both no iron ($n = 6$ trials; RR, 1.21; 95% CI, 1.12–1.31) and oral iron ($n = 3$
trials; RR, 1.37; 95% CI, 0.92–2.05). Time to response was faster in the IV iron group (range, 36–54 days) versus standard-of-care group (range, 46–94 days). IV iron but not oral iron was associated with improved hematopoietic response rates compared to ESA alone. No difference in adverse events was found (n = 4 trials; RR, 0.99; 95% CI, 0.93–1.04), including thromboembolic events (n = 4 trials; RR, 1.03; 95% CI, 0.59–1.80) and cardiovascular events (n = 6 trials; RR, 1.08; 95% CI, 0.65–1.78). There was no difference in all-cause mortality at the end of follow-up (n = 7 trials, 1470 patients; RR, 1.13; 95% CI, 0.75–1.70).

Ferric carboxymaltose is FDA-approved for patients with CKD or an intolerance or poor response to oral iron. It has also been evaluated for the treatment of iron-deficient anemia in patients with dialysis-dependent CKD, inflammatory bowel disease, and others. The observational study from Steinmetz et al evaluated its use in patients with cancer. Of the 639 adult patients from 68 cancer centers in Germany, safety data could be obtained from 619 patients. With doses ranging from 600 to 1500 mg of ferric carboxymaltose, adverse drug reactions were seen in 14 (2.3%) patients and were primarily related to the gastrointestinal tract. Of the 233 patients with follow-up Hb measurements, a median increase of 1.4 g/dL (range, 1.3–1.5 g/dL) was observed with an overall increase of median Hb levels greater than 11 g/dL within 5 weeks of treatment with ferric carboxymaltose. A second observational study of 367 patients with solid tumors or hematologic malignancies demonstrated improved median Hb levels following ferric carboxymaltose alone or in combination with an ESA (1.3 g/dL vs. 1.4 g/dL, respectively) when measured over the 3-month observational period. Stable median Hb levels of 11 g/dL or greater were reached in patients without signs of iron overload. These data suggest that ferric carboxymaltose may be an effective and well-tolerated treatment for CIA.

There remains a paucity of both safety and efficacy data for the use of ferumoxytol in patients with cancer. Ferumoxytol is a colloidal iron oxide that was approved in June 2009 by the FDA for the treatment of iron deficiency anemia in patients with CKD. A recent 812-patient, phase III trial investigating the use of ferumoxytol in patients with anemia due to various causes randomized patients to either the treatment arm (n = 608) or the placebo arm (n = 200). Following treatment with ferumoxytol, 81.1% of patients achieved the primary endpoint (Hb increase ≥2.0 g/dL at week 5) compared to only 5.5% of patients given placebo (P < .0001). After 5 weeks, Hb levels greater than or equal to 12 were seen in 50.5% of patients treated with ferumoxytol versus 2.0% of patients receiving placebo (P < .0001). The incidence of serious adverse events was similar between the two groups (ferumoxytol, 2.6% vs. placebo, 3.0%). While this ferumoxytol study indicates that the drug is well tolerated and can effectively correct anemia, only a small percentage of patients in this study had cancer (n = 39); ferumoxytol was given to 29 of these patients and placebo was given to 10 patients. Although a positive trend in favor of ferumoxytol was demonstrated in the cancer subgroup compared with placebo (ferumoxytol, 51.7% vs. placebo, 30.0%; P < .2478), the difference was not statistically significant. In a randomized phase III study of patients with iron deficiency anemia that had not responded to oral iron, ferumoxytol showed noninferiority to iron sucrose as measured by the proportion of patients who had at least a 2 g/dL increase in Hb from baseline to week 5 following treatment with ferumoxytol (84%; n = 406) versus iron sucrose (81.4%; n = 199). In the cancer subgroup (n = 31), there was a trend favoring ferumoxytol (54.8%) compared to iron sucrose (38.5%). However, noninferiority was not reached, potentially...
due to the small sample size. It should be noted that ferumoxytol may cause interference with MRI scans causing potential false interpretation of organ iron overload. This is especially pertinent in this population that is at risk for serious organ-threatening iron deposition and should be a consideration when selecting the agent for the iron supplementation.

NCCN Evaluation and Definitions of Iron Status

Iron deficiency is reported in 32% to 60% of patients with cancer, most of whom are also anemic. Iron studies, including serum iron, TIBC, and serum ferritin, should be performed prior to ESA treatment in order to rule out absolute iron deficiency, which may respond to oral or IV iron monotherapy without an ESA. Serum iron and TIBC levels may be falsely elevated by diet (reviewed in Collings et al); therefore, fasting iron studies may provide a more accurate representation of iron deficiency. Transferrin saturation should be calculated from these values using the following formula:

\[ \text{TSAT} = \left( \frac{\text{serum iron level} \times 100}{\text{TIBC}} \right) \]

Treatment for iron deficiency is guided by iron status, defined in these guidelines as absolute iron deficiency, functional iron deficiency, possible functional iron deficiency, or no iron deficiency. In the absence of a universal numerical definition of iron deficiency in relevant studies, the NCCN Panel recognizes that ferritin and TSAT values defining absolute and functional iron deficiencies represent moving targets. However, as general guidance, definitions and characteristics of each iron status group are discussed below.

**Absolute Iron Deficiency**

Absolute iron deficiency refers to the depletion of total body iron stores. It is characterized by low Hb, low iron, and high TIBC that result in a TSAT level less than 20% and a ferritin level less than 30 ng/mL. If the TSAT and ferritin parameters are discordant, a low ferritin value should take precedence in determining whether iron supplementation will be beneficial. The reference interval for serum ferritin depends on the specific laboratory used, but in general, the lower the level, the more probable that true iron deficiency is present.

Although IV iron is preferred, either IV or oral iron products alone (without an ESA) are recommended for patients with cancer who develop absolute iron deficiency. If the patient initially receives oral iron and the anticipated response is not seen after 4 weeks, a trial of IV iron should be considered. Periodic evaluation of ferritin and TSAT levels is required as some patients, especially those with continued internal bleeding, may suffer a relapse. If Hb is not improved after 4 weeks following IV iron supplementation, patients should be evaluated for functional iron deficiency. Although data are conflicting in the literature, concerns exist regarding the possibility of IV iron promoting inflammation and bacterial growth. Hence, iron supplementation is not recommended for patients with an active infection.

For further discussion of absolute iron deficiency, see *Clinical Examples of Iron Status, case scenarios 1 and 2.*

**Functional Iron Deficiency**

Functional iron deficiency is defined in these guidelines as a ferritin level between 30 ng/mL and 500 ng/mL and a concurrent TSAT level less than 50%. Functional iron deficiency is a condition in which stored iron is sufficient but bioavailable iron necessary for erythroblast production is deficient. IV iron supplementation with erythropoietic therapy should be considered. IV iron monotherapy in patients with functional iron deficiency who are not receiving ESA therapy can reduce the number of RBC transfusions. For patients who are receiving ESA...
therapy, functional iron deficiency will develop, and these patients will likely benefit from IV iron.

While Hb and TSAT levels will be low, ferritin level usually remains within normal limits. Laboratory diagnosis of this condition was detailed by Thomas and colleagues. Functional iron deficiency may result from cases where infection or inflammation blocks iron transport to the bone marrow, as seen in anemia of chronic disease. Another form of functional iron deficiency often arises following continued ESA use. The overall result is a blunted erythropoietic response to anemia. Hence, iron supplementation will eventually be required in most patients in order to maintain optimal erythropoiesis. IV iron supplementation with erythropoietic therapy should be considered.

For further discussion of functional iron deficiency, see Clinical Examples of Iron Status, case scenario 3.

Possible Functional Iron Deficiency
Possible functional iron deficiency is a condition in which stored iron is sufficient but bioavailable iron necessary for erythroblast production may be deficient. These patients are defined by a TSAT level less than 50% and a ferritin level greater than 500 but less than or equal to 800 ng/mL. Although clinical trials suggest that these patients may have functional iron deficiency, there are insufficient data to support the routine use of IV iron in this setting. Administration of IV iron to these patients should be individualized with the goal of avoiding allogeneic transfusion.

For further discussion of functional iron deficiency, see Clinical Examples of Iron Status, case scenarios 4 and 5.

No Iron Deficiency
Patients with ferritin values greater than 800 ng/mL or a TSAT greater than or equal to 50% are not iron deficient. These patients do not require iron supplementation.

NCCN Recommendations for the Management of Iron Deficiency
As previously discussed, most studies show that IV iron is superior over oral iron and should be used. Low-molecular-weight iron dextran, ferric gluconate, and iron sucrose are recommended parental iron preparations. Ferric carboxymaltose has not been prospectively evaluated, and therefore should only be considered when other parental iron preparations fail. It is indicated for adult patients when oral iron is not tolerated or there is a limited response. Although ferumoxytol is indicated for the treatment of iron deficiency in adult patients with CKD, it has not been adequately evaluated in patients with cancer and may cause interference with MRI scans causing potential false interpretation of organ iron overload.

Common adverse events following FDA-approved doses of parenteral iron include hypotension, nausea, vomiting and/or diarrhea, pain, hypertension, dyspnea, pruritus, headache, and dizziness. Most adverse events associated with iron dextran occur with high-molecular-weight iron dextran. Therefore, the recommended iron dextran product is low-molecular-weight iron dextran. Test doses are required for iron dextran, and are strongly recommended for patients receiving ferric gluconate or iron sucrose who are sensitive to iron dextran or who have other drug allergies. As reactions to the IV iron test dose may be severe, pre-medication of the patient should occur prior to the test dose. Anaphylaxis-like reactions occur within minutes of the test dose but respond readily to IV epinephrine, diphenhydramine, and corticosteroids. It should be noted that patients may develop a reaction to IV iron with later doses, and clinicians should be prepared to
administer appropriate treatment. Delayed reactions to iron dextran may result in adverse events up to 24 to 48 hours following injection.\textsuperscript{146} Severe acute adverse reactions include anaphylaxis with dyspnea, hypotension, chest pain, angioedema, or urticaria. Dosage details for administering parenteral iron therapy are listed in the algorithm (see \textit{Recommendations for Administering Parenteral Iron Products} in the algorithm).

Patients with a baseline TSAT level below 20% had a higher response rate to IV iron supplementation when given in addition to an ESA. As the TSAT level increases from 20\% to 50\%, the response rate is diminished, and the time to a response is prolonged. Hence, for this group, IV iron should only be offered if benefits are likely to outweigh risks.

None of the six studies on iron supplementation in conjunction with ESAs provided instruction on how or when to re-dose iron after the initial cumulative dose has been given. Generally, repeat iron studies are not recommended within 3 to 4 weeks of administration. Clinicians may consider repeating iron studies when the MCV declines or hypochromic RBCs are seen on the peripheral blood.

For patients with disease that fails to respond to iron after 4 to 6 weeks and after the total intended dose has been administered, repeat iron studies may be considered.\textsuperscript{114,118} If evidence exists of iron overload, do not administer IV iron. Subsequent doses of iron should be withheld if the serum ferritin exceeds 800 ng/mL or if the TSAT level exceeds 50\%.\textsuperscript{113-115}

Individuals with a ferritin level greater than 800 ng/mL or a TSAT level greater than or equal to 50\% do not require iron supplementation as they are not considered iron-deficient and will likely not experience functional iron deficiency, even if an ESA is administered.

**Clinical Examples of Iron Status**

The following clinical scenarios illustrate how iron studies may guide iron and ESA treatment of anemia in patients with cancer.

**Patient Case**

FM is a 59-year-old female with no significant past medical history. In addition to a 2-month history of early satiety and 9 kg weight loss, she presented to her primary care provider after acute onset of bloody stools. Abdominal imaging revealed a colon mass and mesenteric lesions. She was referred to an oncologist. Biopsy of the colon mass demonstrated a poorly differentiated adenocarcinoma. Her oncologist has begun palliative treatment with FOLFOX plus bevacizumab chemotherapy, a myelosuppressive regimen. After 2 cycles of chemotherapy, her CBC results are as follows: Hb 8.8 g/dL, Hct 26.7\%, MCV 73 fL, reticulocytes 0.8\%, mean corpuscular Hb 25 pg, red cell distribution width 18.2\%, and platelets 398,000/\mu L. She does not have CKD. Serum folate and vitamin B12 levels are within normal limits. Indirect bilirubin and serum LDH are within normal limits. Bleeding has ceased, but given her baseline anemia and red cell indices, iron studies have also been ordered. Five different scenarios are provided below to illustrate the potential management of this patient depending on various ferritin and TSAT combinations.

**Scenario 1: Serum Ferritin 5 ng/mL & TSAT 4\%**

With a ferritin level less than 30 ng/mL and a TSAT level less than 20\%, this patient has absolute iron deficiency and would benefit from iron repletion. Reducing transfusion requirements remains the goal of therapy. With a baseline Hb of 8.8 g/dL, imminent chemotherapy initiation, and very low iron stores, IV iron repletion is preferred. Oral
iron may not supply bioavailable iron rapidly enough in certain patients.112

**Scenario 2: Serum Ferritin 10 ng/mL & TSAT 22%**

With low ferritin and normal TSAT levels, we can postulate that iron stores are becoming depleted. Iron is being mobilized, but signs of iron-restricted erythropoiesis are beginning to emerge. If the ferritin and TSAT levels are discordant, the low ferritin level should take precedence to determine if IV iron therapy would be beneficial to the patient. Iron would be beneficial in this patient as these laboratory values potentially reflect a transition from an iron-replete to an iron-deficient state. For the same reasons as discussed in scenario 1, IV iron is preferred. It is also possible for TIBC to be low secondary to malnutrition, resulting in a normal TSAT level despite definitive absolute iron deficiency. ESA use should be considered only after iron repletion.

**Scenario 3: Serum Ferritin 580 ng/mL & TSAT 12%**

With normal or elevated ferritin and low TSAT levels, we can assume that iron is either not bioavailable or that the ferritin reflects an acute-phase response, potentially secondary to cancer-related inflammation (functional iron deficiency). Functional iron deficiency may cause iron-restricted erythropoiesis, and there is no ferritin threshold at which we can assume iron supply is adequate for erythropoiesis if the TSAT level is low. Thus, patients with ferritin levels in excess of 100 ng/mL could be treated with IV iron, as discussed in scenario 2. However, in this instance, an ESA should be considered first. This is because as the ferritin level moves across the spectrum from absolute iron deficiency to iron overload, the response to either an ESA or iron will diminish. As a result of limited data to currently support IV iron added to an ESA for patients with a ferritin greater than 800 ng/mL,147 iron should be withheld until hyporesponsiveness to the ESA is noted, or until other signs or symptoms of iron deficiency arise. Concomitant IV iron can be considered as it may increase the percentage of patients with disease that responds to the ESA as well as reduce the time to response.

**Scenario 4: Serum Ferritin 100 ng/mL & TSAT 30%**

As the TSAT level increases from 20% to 50%, the percentage of patients with disease that responds to iron decreases; therefore, this patient may not necessarily require IV iron until the TSAT level trends downward as a result of ESA use. If the anticipated response to ESA is not realized by 4 to 6 weeks, consider repeating iron studies. If TSAT and/or ferritin levels decrease, consider giving IV iron. If iron studies remain unchanged, continue the ESA for a total of 8 weeks of therapy and discontinue thereafter if lack of response persists, and consider RBC transfusion.

**Scenario 5: Serum Ferritin 500 ng/mL & TSAT 40%**

These ferritin and TSAT parameters suggest that functional iron deficiency is unlikely because TSAT is typically low in that condition. Therefore, this patient is unlikely to benefit from iron therapy since he or she is iron replete. In this scenario, an ESA may be considered. ESA use induces functional iron deficiency by increasing iron utilization without the compensatory ability to mobilize storage iron in a timely manner; therefore, iron repletion can be initiated if a response to ESA is not seen and the patient remains transfusion-dependent. Of note, improved response is generally expected as the TSAT level decreases from 50% to 20%. Ultimately, it is up to the treating clinician to determine whether the potential benefits of iron administration are likely to outweigh the risks.

**Future Development**

In the face of current controversy in various aspects of anemia management, well-designed trials are required to answer questions regarding the safety of ESAs for lower-target Hb levels, the role of IV
Iron in reducing transfusion needs, the optimal dose and frequency of IV iron, and both short- and long-term effects of iron supplementation, among others.

Several novel IV iron agents are currently being studied as monotherapy (without an ESA) in CIA. More information about these agents can be found at www.clinicaltrials.gov. Other areas for future development include markers of iron deficiency. Soluble transferrin receptor level has been suggested as a marker of iron deficiency that can aid in differential diagnosis. However, studies are still needed to evaluate the role of this marker in patients with CIA.
NCCN Guidelines Version 2.2017
Cancer- and Chemotherapy-Induced Anemia

References


32. Stanworth SJ, Navarrete C, Estcourt L, Marsh J. Platelet refractoriness--practical approaches and ongoing dilemmas in patient


74. Overgaard J, Hoff CM, Hansen HS, et al. Randomized study of darbepoetin alfa as modifier of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC): Final


128. Van Wyck DB, Mangione A, Morrison J, et al. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in


